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ABSTRACT 
 
Cellular targets for the majority of dietary phytochemicals remain unknown, 
presenting a challenge for the understanding of how these dietary components provide 
health benefits.  Recently a new methodology, drug affinity responsive target stability 
(DARTS), was developed for this purpose. The objective of this study was to evaluate 
the anti-inflammatory properties of mashua (Tropaeolum tuberosum) tuber and acerola 
leaf (Malpighia emarginata) extracts and to identify the protein targets of its 
phytochemicals by using DARTS methodology.   
The first aim was to investigate the anti-inflammatory properties of mashua 
extracts and to identify the cellular targets of its phytochemicals. Mashua 203040 and 
203081 extracts exerted anti-inflammatory properties in LPS-stimulated macrophages. 
Through DARTS methodology we identified pyruvate kinase M (PKM) as a potential 
target of the phytochemicals present in both extracts. Additionally, mashua extracts 
reduced reactive oxygen species (ROS) levels and consequently affected the expression 
of ROS dependent LPS-induced pro-inflammatory genes. LC-MS profiling revealed that 
both mashua extracts contained mainly phenolics and isothiocyantes. In this study, we 
demonstrated that phytochemicals from mashua reduce LPS-induced inflammation in 
RAW264.7 macrophages by targeting PKM and reducing ROS.  
The second aim was to identify the bioactive compounds acting as COX-2 
inhibitors in acerola leaf by using bioassay-guided fractionation and DARTS 
methodology. The leaf extract (F4) was fractionated into three fractions (F1, F2, and F3) 
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and results indicated that F4, F2, and F3 inhibited COX-2 activity. F2 showed the 
highest COX-2 inhibitory effect among the fractions, and also showed binding to COX-2 
by DARTS. Thus, its subfractions (F2A, F2B, and F2C) were further tested for their 
ability to bind and inhibit COX-2 activity. All subfractions inhibited COX-2 activity but 
only F2A and F2C showed binding by DARTS. F2C was further fractionated and only 
fraction F2C4, containing terpenes, inhibited COX-2 activity. In this study, we identify 
the group of compounds from acerola leaf, which are responsible for the inhibition of 
COX-2 activity. 
In conclusion we were able to characterize many of the phytochemicals present 
in mashua tuber and acerola leaf and to identify the putative targets responsible for their 
anti-inflammatory effect in vitro. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Chronic Inflammation and Metabolic Disorders 
Inflammation is an innate or adaptive response of the immune system that is 
triggered by different stimuli or conditions, including infection, tissue injury, (1) and 
dietary stress (2). Upon the induction of an inflammatory response, there is usually a 
sequential release of inflammatory mediators and recruitment of leukocytes to the 
inflammation site. Once these cells reach the inflammation site, they become activated 
and release more mediators, creating a vast communication network between the 
metabolic tissue and immune system cells (3). The inflammatory mediators include 
antimicrobial mediators such as reactive oxygen and nitrogen species, which directly 
target the pathogens (4); chemokines like monocyte chemotactic protein-1(MCP-
1/CCL2), which recruit leukocytes to the inflammation site (5); and cytokines such as 
tumor necrosis factor-α (TNFα), which serve as signaling molecules that coordinate and 
regulate the inflammation response (6, 7).  
In a successful acute inflammatory response, the infectious agent is eliminated, 
the inflammatory response is resolved, and the tissue is repaired (1). The inadequate 
resolution of inflammation or an uncontrolled inflammatory response can lead to a 
chronic inflammation state. Chronic inflammation is usually defined as a pathological 
condition characterized by continuously active inflammatory response, which 
predisposes the host to different metabolic diseases, including diabetes (8), 
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atherosclerosis (9), neurodegenerative diseases, (10) and some types of cancers (11). For 
instance, in an obese host, the excess of nutrients can cause dietary stress in the adipose 
tissue, which induces the production of TNF-α by adipocytes. Consequently, resident 
macrophages become activated and produce more inflammatory mediators, resulting in a 
low-grade chronic inflammatory state. Many studies have shown that this chronic 
inflammation state promotes insulin resistance and metabolic deterioration in obesity 
(12). Furthermore, chronic inflammation plays a role in the development and progression 
of certain cancers such us colon cancer (13). As mentioned previously, in a chronic 
inflammation state there is a constant production of cytokines and other mediators such 
as ROS. These chemical mediators can directly damage cell components (i.e. DNA) and 
also alter the intracellular signaling of the cells. In this scenario, chronic inflammation 
can contribute to tumor initiation by inducing DNA damage and chromosomal 
instability. Also, through the alteration of signaling pathways, it can enhance cell 
proliferation, resistance to apoptosis, stimulated angiogenesis, among other factors that 
contribute to cancer progression, cell invasion, and metastasis (14).  
Macrophage Polarization and Chronic Inflammation 
Macrophages play a central role in many different immune pathological 
phenomena that lead to chronic inflammation and associated diseases. These include the 
over-production of pro-inflammatory cytokines such as TNF-α and interleukin 1-beta 
(IL-1β) and other inflammatory mediators like NO and ROS (15).  Due to the critical 
role of cytokines and other inflammatory mediators in the development and pathogenesis 
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of chronic inflammation and associated conditions, they have become an important 
target for the intervention of these diseases (7).  
To understand the regulation of inflammatory mediators by macrophages, it is 
crucial to define the mechanisms that regulate macrophage metabolic activity (16). In 
response to different environmental signals, macrophages can reprogram into many 
different phenotypes with diverse functions. Despite the various phenotypes of 
macrophages, there are two mainly recognized, the classically activated macrophages or 
M1 and the alternative activated macrophages or M2 (17). Macrophages polarize into 
M1 phenotype upon the stimulation with interferon-γ (IFNγ) or certain Toll-like receptor 
(TLR) ligands such as lipopolysaccharide (LPS). This phenotype has a strong 
microbicidal activity and is characterized by the production of pro-inflammatory 
cytokines such as TNF-α and other inflammatory mediators such as ROS and NO. 
Instead, exposure to cytokines IL-4 and IL-3 polarizes macrophages to M2 phenotype. 
This phenotype helps clear extracellular parasites, resolve the inflammatory response, 
and promotes tissue remodeling, among other functions (17, 18).  
Each macrophage phenotype metabolizes glucose differently according to their 
function and their needs (Biswas and Mantovani 2012). Normally, resting cells produce 
ATP through a combination of glycolysis and mitochondrial respiration. During 
glycolysis, glucose is converted to pyruvate, which enters the tricarboxylic acid (TCA) 
cycle in the mitochondria and becomes oxidized to generate ATP. However, M1 
macrophages, similarly to cancer cells, exhibit a different metabolism. These cells, 
besides energy, have a high demand for biosynthetic precursors used for the synthesis of 
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pro-inflammatory proteins (19). To meet these new needs, the cells switch their 
metabolism from a low rate of glycolysis followed by the oxidation of pyruvate in the 
mitochondria, to a high rate of glycolysis and a much lower rate of oxidative 
phosphorylation. Pyruvate is converted into lactate by lactate dehydrogenase (LDH) in 
the cytosol, instead of entering the TCA cycle. This change in the metabolic profile 
involves a switch in the expression of many genes such as glucose transporter 1 
(GLUT1), lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase 1 (PDK1). 
This phenomenon occurs under aerobic conditions and is known as the “Warburg effect” 
after Otto Warburg, who first defined it (6, 19, 20). Instead, M2 macrophages continue 
to obtain most of their energy through oxidative phosphorylation which helps them 
accomplish their function in tissue remodeling and repair (16) (Figure 1). 
Targeting the Warburg effect has become an interesting intervention approach for 
inflammatory related diseases, due to its critical role in M1 polarization and consecutive 
over production of pro-inflammatory mediators. Some of the possible targets of the 
Warburg effect include hexokinase, pyruvate dehydrogenase kinase (PDK), and pyruvate 
kinase M2 (PKM2), among others (19).   
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Figure 1 Schematic illustration of metabolic pathways of normal resting cells (A) 
compared to activated immune cells or cancer cells (B). Adapted from B. Kelly and L. 
O’Neill, 2015 (6). 
 
 
Inflammatory Pathways with a Special Focus on NF-κB  
Three inflammatory pathways have been mainly implicated in the pathogenesis 
of inflammatory diseases: IKK–nuclear factor-κB (NF-κB), Jak-Stat and mitogen-
activated protein kinase (MAPK) pathways. Moreover, these pathways interact with one 
another and with other pathways in a highly regulated manner creating a vast signaling 
network between immune cells and cells from different tissues (21-23).  One of the most 
studied pathways is the NF-κB pathway. Initially, it was believed that this pathway was 
mainly activated in immune cells, but now it is recognized that it can be activated in 
most cells including adipose tissue, liver, and central nervous system (24).  NF-κB is a 
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transcription factor that regulates the expression of various genes, mainly those with pro-
inflammatory and anti-apoptotic functions (25). The activation of the NF-κB pathway in 
macrophages and tissue cells plays a central role in the initiation and promotion of the 
inflammatory response. The signaling cascade that promotes the activation of NF-κB 
starts when cytokines or pathogen-associated molecular patterns (PAMPs) stimulate 
receptors located in the surface of the cell, including toll-like receptors (TLRs) (24). NF-
κB dimers are normally sequestered in the cytosol of resting cells by inhibitory proteins 
known as the inhibitor of κB (IκB), which prevent its nuclear translocation. Once cytokines 
or PAMPs initiate the signaling cascades, the inhibitor of kB kinase (IKK) complex is 
activated. The activated IKK phosphorylates IκB, promoting its degradation and release 
of the NF-κB (24, 25). Free NF-κB translocates to the nucleus and promotes the 
expression of pro-inflammatory genes such as COX-2, IFN-β (17), and eventually iNOS 
(26, 27).   
Role of Reactive Oxygen Species in Inflammation 
ROS are molecules with strong oxidizing capabilities that are normally produced 
as byproducts of oxygen metabolism. The major ROS produced by cells are superoxide 
anion (O2
-●
), hydroxyl radical (OH
●
), and hydrogen peroxide (H2O2).  ROS are mainly 
generated as byproducts of mitochondrial metabolism through the electron transport 
chain (28, 29). However, another important source of ROS, especially in macrophages 
and endothelial cells, is the enzymatic reaction catalyzed by NADPH oxidases (NOX). 
Production of ROS by NOX is triggered by LPS and pro-inflammatory cytokines such as 
TNFα, and this is crucial in the inflammatory response (28). At high concentrations, 
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ROS can have harmful effects on cells because they can oxidize and damage cellular 
constituents such as proteins, lipids, and DNA. However in normal conditions, ROS play 
a crucial role in different cellular functions, such as cell proliferation, chemotaxis, and 
apoptosis (28, 29). In normal conditions, the presence of antioxidants balances the 
damaging effects of ROS. Some of these antioxidants are enzymes such as catalase and 
glutathione peroxidase or other molecules, such as glutathione and carotenoids (30). In 
an inflammation state, ROS, besides serving as a microbicidal agent, regulates different 
signaling pathways implicated in an inflammation response. For instance, ROS plays a 
major role in the activation of NF-κB (31, 32) and hypoxia-inducible factor 1α (HIF1α), 
which is a central regulator of the Warburg effect (33). In this scenario, ROS is an 
important mediator in the initiation and progression of inflammation related metabolic 
diseases (28).   
Dietary Phytochemicals and Inflammation  
It is now recognized by the scientific community that food, besides providing us 
with nutrients, can also help us prevent certain diseases. Many groups of foods have 
been shown to be beneficial for the prevention of different diseases. For instance, studies 
suggest that the high consumption of cereal fiber, whole grains, fruits, and vegetables is 
associated with a lower risk of colorectal cancer (34, 35); also, the consumption of fish, 
fruits and vegetables reduce the risk of stroke and coronary heart disease (36-39). In 
addition, the use of medicinal plants for the treatment of different diseases is a common 
practice in many cultures around the world (40). For example, Mashua tuber 
(Tropaeolum tuberosum) has been traditionally and extensively used as a medicinal plant 
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in the Andean region, for health improvements related to kidney and liver pain, skin 
eczemas, and prostate disorders (41). 
Fruits, vegetables, and other edible plants such as herbs and spices or plant 
products such as tea and wine are rich in phytochemicals. Many of these chemicals 
found in plants have been shown to have bioactive properties, and are known to be 
responsible for many of the health beneficial properties attributed to plants (42).  Most of 
these phytochemicals are secondary metabolites, which do not appear to be involved in 
the plant’s photosynthesis, respiration, growth, and development, but possess other 
functions. Some of the functions that secondary metabolites have in plants are protection 
of plants from herbivores and microbial infection, attraction of pollinators, allelopathic 
agents, and protection against UV (43).  Phytochemicals can be classified based on their 
biochemical origin as carotenoids, phenolics, alkaloids, nitrogen-containing compounds, 
and organosulfur compounds (44). Many of these chemicals have shown to reduce 
inflammation and related diseases through different mechanisms, by interfering at 
several points of cellular inflammatory pathways (45). Some of the mechanisms through 
which phytochemicals modulate inflammation are exerting antioxidant properties (46-
48) and scavenging reactive oxygen species (49-51), modulating the activity of pro-
inflammatory enzymes such as iNOS (52) and COX-2 (53-55), and modulating different 
inflammatory pathways such as NF-κB (56-58), STATs (59, 60), and MAPKs pathways 
(61-63). The modulation of inflammation by phytochemicals through any of the above-
mentioned mechanisms usually results in a reduction of pro-inflammatory mediators 
which positively impacts inflammation and related diseases (45).  Moreover, many 
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phytochemicals have more than one target (64), and when several of those 
phytochemicals are consumed concurrently the effect is superior, which makes  it very 
attractive for therapeutic use (65).  
Target Identification of Bioactive Compounds 
Cellular targets for the majority of dietary phytochemicals remain unknown, 
presenting a challenge for understanding how these dietary components provide health 
benefits. The lack of knowledge about the molecular targets responsible for the 
beneficial and/or adverse side effects of most dietary compounds limits their potential 
use as medicinal foods, supplements or drugs, and their regulation (64, 66). Despite the 
great effort in the past decades to establish methods for the identification of the cellular 
targets of small molecules, this step, in many cases, continues to be the most challenging 
and the most limiting in chemical biology research. The reasons behind this deficit 
include the different chemical nature of bioactive molecules and their varying affinity 
for targets, the different nature of the target proteins and their varying abundance, and 
analytical methods not being sufficiently developed (66). 
 There are different methods and technologies that have been reported to identify 
proteins targets. These approaches can fundamentally be classified into direct (target-
based) or indirect (phenotype-based) approaches (67, 68). The target-based approaches 
provide the most direct route to find the target protein. Affinity chromatography is a 
direct approach and remains the most widely used method for this purpose (69, 70). In 
affinity chromatography, the small molecule is usually attached to a solid support (e.g., 
Affi-Gel agarose beads) or labeled with an affinity tag (e.g., biotin). Then, proteins 
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bound to the small molecule are purified and identified using mass spectrometry 
analysis. Once the potential targets are identified, further studies need to be done to 
confirm the direct binding and its biological relevance (67, 69, 71). Although affinity-
based target identification techniques directly detect the target, these are limited due to 
the necessity to derivatize the small molecule without losing bioactivity. In addition, 
these studies are time-consuming and require high expertise in medicinal chemistry; and 
most of the time the small molecule cannot be modified without losing its activity (72).    
On the other hand, the indirect or phenotype-base approach identifies possible 
protein targets by profiling the biological effects of the small molecules. In this 
approach, when the compound of interest interferes with a cellular event whose 
regulatory pathways have been reported, protein targets can be narrowed down as 
possible candidates. Proteomics and genomics analyses have helped gather information 
about the biological activity of small molecules and target profiling. The disadvantage of 
this approach is that it depends on the drug’s ability to induce specific cellular or 
biochemical responses (67-69, 73). 
Drug Affinity Responsive Target Stability (DARTS) 
Drug affinity responsive target stability (DARTS) is a simple and universally 
applicable target identification approach recently developed, that overcomes many of the 
limitations of other target identification methodologies.  This approach relies on the 
drug-protein interaction but does not require modification of small molecules. The 
strategy of DARTS is based on the principle that binding of small molecules will 
stabilize target proteins, making them less susceptible towards proteolysis (74). Proteins, 
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under physiological conditions, are in a dynamic equilibrium, at which they can acquire 
alternative conformations and exhibit local reversible unfolding. When a ligand binds to 
a protein, the equilibrium shifts to a thermodynamically more stable state in which the 
target proteins experience less conformational fluctuations and unfolding. Under these 
conditions, the resistance to denaturation and proteolysis is markedly increased (72, 75-
77).  Lomenick et al (74), took advantage of this principle and proposed to use it to 
identify potential protein targets without derivatizing or immobilizing the small 
molecules. They also suggested methodologies that can be used together with DARTS to 
identify the protease-protected proteins.  A schematic illustration of DARTS is shown in 
Figure 2.   
The overall procedure of DARTS is relatively standardized, but there are several 
steps that must be modified for each experiment, which include the source of protein, 
selection of small molecule and protease, and their concentration ranges. For the source 
of protein, generally, any cell type that is sensitive to the biological effects of the small 
molecule can be used. The small molecule believed to bind proteins should meet certain 
criteria to be suitable for DARTS. This includes mainly small molecules that are not 
susceptible to proteolysis. There are many different proteases available that could be 
used with DARTS, but the ones that have primarily been used are thermolysin and 
Pronase. Briefly, in DARTS the cell lysates (or pure protein) are prepared and 
quantified, the compound of interest and a negative control are added, and the 
proteolysis is preformed (78, 79).  
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Figure 2 Flowchart of DARTS strategy used to identify protein targets of small 
molecules. Adapted from E. Tashiro and M. Imoto, 2012 (67). Mammalian or yeast cell 
lysates are incubated with the small molecule of interest, followed by the digestion of the 
mixture by the selected protease (usually pronase or thermolysin). The protein samples 
are separated by SDS-PAGE electrophoresis and the gel is stained with coomassie blue 
or silver staining. The lanes of the stained gel are analyzed for bands that are more 
intense in treated samples over the control. Once band differences are found, each band 
can be cut out, digested with trypsin, and analyzed with mass spectrometry to identify 
the potential target of the small molecule (74). 
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In order to identify targets of the compound of interest, one or more proteomics 
techniques must be used after the proteolysis. These techniques include but are not 
limited to Western blotting, SDS-PAGE, and gel-free MS-based proteomics. The 
simplest procedure for DARTS involves separation of the digested drug-treated and 
control protein samples by SDS–PAGE, staining the gel with Coomassie Blue, or silver 
stain, and analyzing the lanes of the gel for bands that are more intense in treated 
samples over the control. Once band differences are found, each band can be cut out, 
digested with trypsin, and analyzed by mass spectrometry (MS/MS) (72, 78, 79).  
Further studies need to be done to confirm the direct binding to the target protein and its 
biological relevance. The key advantage of DARTS is that it uses native small 
molecules; therefore it can potentially be used to identify binding targets for any small 
molecule even without knowing the chemical identity or purity of the compound.  Thus, 
DARTS is suitable for target identification of bioactive natural product extracts. The 
main limitation of DARTS resides primarily in its low sensitivity especially for proteins 
of lower abundance.  There is the need to use additional methods that will assist in 
finding more subtle differences in protein abundance. Another limitation of DARTS is 
that some proteins may not be stabilized sufficiently by ligand binding leading to false 
negatives (72, 74). DARTS has been used in different studies to identify the cellular 
targets of different compounds. For instance, eIF4A was identified as the target of 
resveratrol through the use of DARTS (74). Also, this approach was used to reveal that 
grape seed extract (GSE) targets endoplasmic reticulum (ER) stress response proteins in 
human colon cancer cells (80) and the dietary compound isoliquiritigenin targets GRP78 
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in breast cancer stem cells (81). In addition, DARTS was used in the development of a 
C-terminal Hsp90 inhibitor, KU174, which demonstrates anti-cancer activity in prostate 
(82). 
Objective and Hypotheses 
Overall Objective and Central Hypothesis  
Overall Objective: To evaluate the anti-inflammatory properties of mashua tuber and 
acerola leaf extracts and to identify the protein targets of its phytochemicals by using 
DARTS methodology.  
Central Hypothesis: The phytochemicals present in mashua tuber and acerola leaves 
will suppress inflammatory markers and DARTS will allow the identification the 
associated-protein targets.  
Specific Aims 
Aim 1 (Chapter II): To investigate the anti-inflammatory properties of mashua extracts 
in RAW 264.7 macrophages and to identify the protein targets of its phytochemicals by 
using DARTS methodology.  
Hypothesis: Mashua extracts will suppress inflammation in RAW 264.7 macrophages 
and the use of DARTS will allow the identification the associated-protein targets.  
Objectives 
1.1 To determine the anti-inflammatory properties of mashua extracts in 
RAW264.7 macrophages. 
1.2 To characterize the phytochemicals from mashua. 
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1.3 To use DARTS methodology to determine the protein targets of mashua 
phytochemicals in RAW264.7 macrophages. 
1.4 To determine the mechanism of action by which mashua phytochemicals 
exert their anti-inflammatory properties in RAW264.7 macrophages.  
1.5 To describe the Warburg effect in LPS stimulated RAW264.7 macrophages. 
Aim 2 (Chapter III): To identify the bioactive compounds acting as COX-2 inhibitors 
in acerola leaf extract by using bioassay-guided fractionation and DARTS methodology.  
Hypothesis: Bioassay-guided fractionation and DARTS will allow the identification of 
phytochemicals acting as COX-2 inhibitors in acerola leaf extract.  
Objectives 
2.1 To evaluate the effect of acerola leaf extract and its components on COX-2 
activity.  
2.2 To characterize the phytochemicals from acerola leaves. 
2.3 To use bioassay-guided fractionation and DARTS methodology to identify 
the bioactive compounds acting as COX-2 inhibitors in acerola leaf extract. 
2.4 To evaluate DARTS as a screening technique.  
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CHAPTER II  
TARGET IDENTIFICATION USING DARTS: MASHUA (TROPAEOLUM 
TUBEROSUM) EXTRACTS EXERT ANTI-INFLAMMATORY PROPERTIES AND 
ATTENUATE THE LPS-INDUCED WARBURG-LIKE EFFECT IN RAW264.7 
MACROPHAGES BY INHIBITING PYRUVATE KINASE M AND REDUCING ROS 
 
Overview 
Cellular targets for the majority of dietary phytochemicals remain unknown, 
presenting a challenge for understanding how these dietary components provide health 
benefits. The Andean tuber mashua (Tropaeolum tuberosum) has sparkled interest 
because of its history in traditional medicinal use. The objective of this study was to 
investigate the anti-inflammatory properties of mashua extracts and to identify the 
cellular targets of its phytochemicals. The extracts of six genotypes of mashua (203081, 
203070, 203040, 203109, 203003 and 203021) were screened for their anti-
inflammatory properties using RAW 264.7 macrophages. Results indicated that all 
mashua extracts reduced (P≤0.05) nitric oxide (NO) levels and all, except for 203076, 
reduced (P≤0.05) reactive oxygen species (ROS) after 19 h of LPS stimulation. Extracts 
203040 and 203081 were the most active to reduce both NO and ROS production, and 
thus were selected to further study the cellular targets of its phytochemicals.  Through 
DARTS methodology we identified pyruvate kinase M (PKM) as a potential target of the 
phytochemicals present in both extracts. The biological relevance of the binding of 
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mashua phytochemicals to PKM was validated by showing that both extracts inhibit 
pyruvate kinase (PK) activity. Furthermore, mashua extracts reduced LPS- induced PK 
activity, lactate levels, mitochondrial dehydrogenase activity and GLUT1 gene 
expression, indicating the effect of mashua on the LPS-induced Warburg effect. 
Additional results showed that mashua extracts reduced early (6 h) and late (19 h) ROS 
levels and consequently affected the expression of ROS dependent LPS-induced pro-
inflammatory genes such as IL-1β, TNFα, iNOS, COX-2 and IFN-β. LC-MS profiling 
revealed that both mashua extracts contained mainly phenolics and isothiocyanates. In 
order to understand the identity of the mashua phytochemicals that possess the anti-
inflammatory properties, mashua 202040 and 203081 fractions (F1, F2, F3, F4, 
F4MeOH and F4H2O) were evaluated for their effects on LPS-induced ROS and NO, 
and their ability to bind to PKM2. Results showed that both, phenolics and 
isothiocyantes in both mashua extracts have anti-inflammatory properties. In this study, 
we demonstrate that phytochemicals from two genotypes of mashua reduce LPS-induced 
inflammation in RAW264.7 macrophages by targeting PKM and reducing ROS.  
Introduction   
Cellular targets for the majority of dietary phytochemicals remain unknown, 
presenting a challenge for understanding how these dietary components provide health 
benefits.  Despite the great effort in the past decades to establish methods for the 
identification of the cellular targets of small molecules, this step, in many cases, 
continues to be the most challenging and the most limiting in chemical biology research 
(66, 67). The reasons behind this deficit include the different chemical nature of 
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bioactive molecules and their varying affinity for targets, the different nature of the 
target proteins and their varying abundance, and analytical methods not being 
sufficiently developed (66). Recently a new methodology, drug affinity responsive target 
stability (DARTS), was developed for this purpose. DARTS is simple and universally 
applicable target identification approach that overcomes some of the limitations of 
traditional methods. This approach is based on the lower susceptibility to proteolysis 
after the drug is bound to the protein target. The key advantage of DARTS over other 
target identification is that the small molecules are used without the need for chemical 
modification. Because DARTS is not limited by the chemical structure of the drug, it can 
be used to identify molecular targets for any small molecule, even without knowing its 
chemical identity or purity (72, 74). 
Chronic inflammation is a pathological condition characterized by continued 
active inflammation response and has been implicated in the development of a variety of 
diseases, including obesity, diabetes (8), atherosclerosis (9), neurodegenerative diseases 
(10) and some types of cancers (11). Macrophages play a central role in many different 
immune pathological phenomena that lead to chronic inflammation and associated 
diseases. These include the over-production of pro-inflammatory cytokines such as 
tumor necrosis factor-alpha (TNF-α) and interleukin 1-beta (IL-1β) and other 
inflammatory mediators like reactive oxygen species (ROS) and nitric oxide (NO) (15). 
Recently, there have been new insights on the importance of metabolic changes in 
macrophages on its activation and the resultant inflammatory response. Similar to tumor 
cells, LPS-activated macrophages have the ability to switch from oxidative 
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phosphorylation to aerobic glycolysis, a phenomenon known as the “Warburg 
Effect”(19). Pyruvate kinase M2 (PKM2), a protein kinase and transcriptional 
coactivator, plays an essential role in the Warburg Effect and the in the activation of 
macrophages. Thus, PKM2 has emerged as a novel target for inflammation and related 
diseases (83, 84). 
Natural food products have gained interest in the past decades as new sources of 
health beneficial agents due to their usually low toxicity in humans. Mashua 
(Tropaeolum tuberosum) is an Andean tuber crop that belongs to the Tropaeolaceae 
family.  Mashua has been cultivated since the time of the Incas and is mainly found in 
the high Andes from Colombia to northwest Argentina. Mashua tubers are usually 5–15 
cm long and 3–6 cm broad in their distal part and can vary considerably in shape and 
color. The tuber skin can display white, yellow, purple or red tones and some of them 
present mottled or striped patterns. Mashua has been traditionally and extensively used 
as a medicinal plant for health improvements related to kidney and liver pain, skin 
eczemas and prostate disorders (41). Studies on the phytochemical composition of 
mashua have indicated the presence of glucosinolates and its hydrolysis product, 
isothiocyanates (85-87) and phenolic compounds (88, 89). The glucosinlates that have 
been reported in mashua include p-methoxybenzyl, 2–propyl, 2–butyl, 4-hydroxybenzyl 
and benzyl glucosinolates (85-87). Among the phenolic compounds that have been 
reported in mashua are gallic acid, gallocatechin, epigallocatechin, procyanidin B2 and 
epigallocatechin derivatives, different hydroxycinnamic and hydroxybenzoic acid 
derivatives and rutin and/or myricetin derivatives (90). For purple colored tubers the 
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major anthocyanins found were delphinidin di- and tri-glycosides acylated with acetic 
acid (89). Mashua has been shown to possess anti-microbial and nematocidal properties 
attributed to the presence of isothiocyanates  (91). Also, mashua has been shown to 
protect against LDL oxidation and oxidative hemolysis of erythrocytes (92). The 
antioxidant properties of mashua have been mostly attributed to the phenolic compounds 
present in this tuber (93).  
The objective of this study was to investigate the anti-inflammatory properties of 
mashua extracts and to identify the cellular targets of its phytochemicals. Moreover, LPS 
stimulated RAW 264.7 macrophage cell line was investigated as a model of the Warburg 
effect.  
Materials and Methods 
Freeze dried tubers of six genotypes of mashua (Tropaeolum tuberosum) were 
supplied by the International Potato Center (CIP, Lima, Peru). Upon arrival at Texas 
A&M University, the samples were frozen and kept at −80 °C until use. The following 
chemicals were used in the experiments: Lipopolysaccharide (LPS), 
Diphenyleneiodonium (DPI), 2′,7′-Dichlorofluorescin diacetate (DCFA), Griess reagent, 
Sodium nitrite solution, Dulbecco’s Modified Eagle’s Medium (DMEM)/low glucose, 
phenol red-free DMEM/low glucose, penicillin/streptomicyn mixture, DMSO and Fetal 
Bovine Serum (FBS) were purchased from Sigma (St. Louis, MO). Glucose and sodium 
bicarbonate were purchased from Acros Organics (Fair Lawn, NJ) and sodium 
bicarbonate from Mallinckrodt Chemicals (Phillipsburg, NJ). Pronase and Protease 
Inhibitor Mixture EDTA-free were purchased from Roche Applied Science 
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(Indianapolis, IN). Disuccinimidyl suberate was purchased from Thermo Scientific 
Pierce (Waltham, MA). The CellTiter 96® AQueous non-radioactive cell proliferation 
assay kit was purchased from Promega (Madison, WI) and the Nuclear Extract Kit from 
Active Motif (Carlsbad, CA). Antibodies against PKM2, PKM1 and ACTIN were 
purchased from Cell Signaling Technology (Danvers, MA). Macrophages RAW 264.7 
(cell line TIB-71™) was acquired from the American Type Culture Collection (ATCC) 
(Manassas, VA).  
Extraction and Fractionation  
The sample preparation and fractionation procedure is illustrated in Figure 3. A 4 
g portion of lyophilized powder of mashua was dissolved in a mixture of 
MeOH/acetone/H2O (5:4:1) and placed in a shaker for 12 hours at 4°C. The extract was 
removed and new extraction solvent was added. This procedure was repeated two 
additional times. The extract was then filtered through Whatman #1 filter paper and 
evaporated at 45 °C using a rotavapor (Büchi, Switzerland). The remaining aqueous 
extracts (5 ml) were loaded into a SEP Pack C18 cartridge (55−105 μm, Waters Corp., 
Milford, MA) previously conditioned to pH 7.0. The cartridge was first washed with 150 
mL of water (pH 7.0). After, compounds were eluted with 50 ml of ethyl acetate, 50 ml 
of acetone and 50 ml of methanol, respectively. The water from the wash was adjusted to 
pH 2.0. This mixture of compounds was loaded into a second cartridge previously 
conditioned at pH 2.0.  
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Figure 3 Extraction and fractionation scheme used for mashua to obtain fractions F1, 
F2, F3, and F4 (A) and F4 H2O and F4 MeOH (B). 
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The compounds bound to the matrix of the second cartridge were later eluted 
with 50 mL of methanol. The four fractions obtained were mixed (mashua extract) or left 
as individual fractions (F1, F2, F3, F4) (Figure 3A). Fraction F4 was further cleaned to 
remove remaining sugars. For this, the sample was loaded into a SEP Pack C18 cartridge 
previously conditioned to pH 2.0. The cartridge was first washed with 150 mL of water 
(pH 2.0) and then the compounds were eluted with 50 ml of methanol to obtain fractions 
F4H2O and F4MeOH respectively (Figure 3B).   Extracts and fractions were evaporated 
at 45 °C using a Centrivap (Labcono) and stored at −20 °C.  
During the extraction process a yield of ~ 82, ~ 94, ~ 85, ~ 88, ~ 149, and ~ 58 
mg of a MeOH/acetone/H2O solvent crude extract powder was obtained from each 4 g of 
freeze-dried 203003, 203021, 203040, 203076, 203109 and 203081 mashua powder, 
respectively. For mashua 203081, during the fractionation process, a yield of ~ 36, ~ 17, 
~ 12 and ~ 67 mg of fraction powders were obtained for F1, F2, F3 and F4 fractions 
respectively, per each 4 g of the freeze-dried mashua powder. For mashua 203040, 
during the fractionation process, a yield of ~ 36, ~ 32, ~ 31.4 and ~ 62 mg of fraction 
powders were obtained for F1, F2, F3 and F4 fractions respectively, per each 4 g of the 
freeze-dried mashua powder. Additionally, F4 was further fractionated with yields of  ~ 
24.5 and ~ 6.1 mg of F4H2O and F4MeOH respectively for mashua 203081 and of ~ 
22.9 and ~ 4.4 mg of F4H2O and F4MeOH respectively for mashua 203040, per each 0.3 
g of the dried F4 mashua powder. 
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LC-MS Analysis and Conditions 
Samples were dissolved in MeOH and 10 µl at a concentration of 5 mg/ml was 
injected into the LC-MS instrument for analysis. The system used was a Surveyor 
(Thermo Scientific, USA) coupled to Surveyor DAD. The eluents were 
acetonitrile/methanol (1:1), formic acid (0.5:99.5, v/v) (phase A) and formic acid–water 
(0.5:99.5, v/v) (phase B). The applied elution conditions were: 0-2 min, 2% A, 98% B; 
3-5 min, 5%A, 95% B, 5-30 min, 20% A, 80% B; 30-72min, 35% A, 65% B; 72-83 min, 
100% A, 0% B; 83-85 min was held isocratic, 100% A; 87-90min 2% A, 98% to the 
starting condition. The chromatograms were monitored at 330, 280, 210 nm; and 
complete spectral data were recorded in the range 200–600 nm. A reversed-phase 
Phenomenex (Torrance, USA) Luna C18 column (150mm×4.6mm i.d. and particle size 
3_m) with a Waters Nova-Pack C18 guard column (10mm×3.9mm i.d, 4_m) was used 
and a flow of 200 µL/min from the DAD eluent was directed to the ESI interface using a 
flow-splitter. Nitrogen was used as desolvation gas, at 275°C and a flow rate of 60 L/h, 
and no cone gas was used. Mass spectra were obtained on a MS Finnigan LCQ Deca XP 
Max,  ion trap mass spectrometer coupled at the exit of the diode array detector and 
equipped with a Z-spray ESI source, and run by Xcalibur version 1.3 software 
(Thermofinnigan-Surveyor, San José, USA). A potential of 1.5 kV was used on the 
capillary for positive ion mode. The source block temperature was held at 120
°
C. 
Analysis of Total Phenolics (TP)  
Total phenolics were determined using the method described by Swain and Hillis 
(94). The extract was dissolved in methanol (30 mg of powder extract/ml of methanol).  
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Methanolic extracts (13 μL) were diluted with nanopure water (208 μL) in a 96-well 
microplate well, followed by the addition of 0.25 N Folin–Ciocalteu reagent (15 μL). 
The mixture was incubated for 3 min, and then, 1 N Na2CO3 (26 μL) was added. The 
final mixture was incubated for 2 h at room temperature in the dark. Spectrophotometric 
readings at 725 nm were collected using a plate reader (Synergy HT, Bio-Tek 
Instruments, Inc., Winooski, VT). Total phenolics were expressed as mg chlorogenic 
acid equivalents (CAE)/mg of crude extract. 
Cell Culture and Treatment of Mashua Extracts and Fractions  
Raw 264.7 macrophages were grown in the DMEM-low glucose (pH 7.2 – 7.4) 
including 4 g/l glucose, 3.7 g/l sodium bicarbonate, 10% fetal bovine serum (FBS) and 
antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) in a humidified 
atmosphere with 5% CO2 at 37°C. Cells were used at a passage of 3 to 8 in this study. 
For treatments of cells with mashua extracts and its fractions (F1, F2, F3, F4, F4H2O, 
and F4MeOH), the cells were plated at 0.5×105 cells/well in a 96-well black or clear 
bottom plates (Costar, Cambridge, MA) for MTS test, NO/ROS and lactate 
measurements, and at 0.5×106 cells/well in 6-well plate (BD Biosciences, Franklin 
Lakes, NJ) for gene expression, protein expression, crosslinking and pyruvate kinase 
activity analysis, and then cultured overnight. The cells were treated with the growth 
medium containing 1 µg/ml LPS either with or without 5 h-pre-treatment of mashua 
extracts and its fractions. Cells were stimulated with LPS for either 6 h or 19 h and 
treated with mashua extracts and its fractions for either 11 h or 24 h (including pre-
treatment), depending on the experiment. Mashua extracts and its fractions were 
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dissolved in the growth medium including 0.5 % DMSO, which was used as a control in 
all experiments. Finally, cells and medium at the time points indicated were used for 
various measurements in this study. 
Cell Viability and LPS-Induced Mitochondrial Dehydrogenase Activity  
Macrophages were plated at 0.5×105 cells/well in 96-well clear bottom plates 
(Costar) and cultured overnight. For the cell viability test, cells were treated with mashua 
extracts and its fractions for 24 h. For the measurement of mitochondrial dehydrogenase, 
cells were stimulated with LPS for 19 h either with or without 5 h-pre-treatment of 
mashua extracts and its fractions. Cell viability and mitochondrial dehydrogenase 
activity were evaluated using the MTS assay kit (Promega, Madison, WI), according to 
the manufacturer’s instructions. The quantity of formazan product was measured at 490 
nm and is directly proportional to the mitochondrial dehydrogenase activity (95).  
Detection of Extracellular Nitric Oxide and Intracellular Reactive Oxygen Species 
Production 
Macrophages were plated at 0.5×105 cells/well in a 96-well black and clear 
bottom plates (Costar) and cultured overnight. The cells were stimulated with LPS for 
times indicated in this study either with or without 5 h-pre-treatment of mashua extracts 
and its fractions as described above. Finally, cells and medium were used for the ROS 
and NO assays, respectively.  
First, the nitric oxide (NO) production was assessed as the accumulation of nitrite 
(NO2
−) in the medium using a colorimetric reaction with Griess reagent. Briefly, 50 µl of 
cell culture supernatants were obtained at 19 h after LPS treatment and 100 mM sodium 
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nitrite solution was diluted with nanopure water for the preparation of standards from 10 
to 100 µM.  Subsequently, the cell supernatants and standards were mixed with an equal 
(1:1) volume of Griess reagent and finally absorbance was measured at 540 nm using a 
96-well microplate reader (Synergy HT, Bio-Tek Instruments, Inc., Winooski, VT). 
Second, intracellular ROS production was measured by 2′,7′-Dichlorofluorescin 
diacetate (DCFA).  Briefly, the cell culture medium was removed by aspiration at times 
indicated in this study after the LPS challenge, and subsequently cells were exposed to 
10 µM DCFA in phenol red/FBS-free DMEM for 30 min, then washed twice with the 
phenol red/FBS-free DMEM. Finally, fluorescence was read immediately at wavelengths 
of 485 nm for excitation and 528 nm for emission on a 96-well microplate reader 
(Synergy HT, Bio-Tek Instruments, Inc., Winooski, VT).    
DARTS  
The target identification using drug affinity responsive target stability (DARTS) 
methodology used was based on the protocol by Lomenick et al. (78). Macrophages 
were plated at 1 ×10
6
 cells/well in 150 x 25 mm clear plates and cultured overnight. The 
cells then were stimulated with LPS for 19 h. Subsequently, cells were washed twice 
with DPBS and lysed with M-PER (Pierce) supplemented with protease and phosphatase 
inhibitors. Protein concentrations were determined by the Pierce BCA protein assay kit 
(Thermo Fisher Scientific, Rockford, IL). Lysates were incubated with 400 μg/ml of 
mashua extracts, 400 μg/ml of mashua fractions or DMSO (control) for 3 h at room 
temperature.  Each sample was then divided into two to six aliquots, each of which 
underwent proteolysis with pronase or mock proteolysis, for 25 min at room 
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temperature. A 1:250, 1:500, 1:1000, 1:2500 and/or 1:5000 ratios of Pronase versus cell 
lysates protein concentration were used for proteolysis. Proteolysis was stopped by 
addition of loading buffer or protease inhibitor, and this was followed by coomassie blue 
staining, silver staining or western blot analysis. Commassie blue and silver staining 
were used to visualize the in gel band protection by mashua extracts. The target protein 
was cut out of the gel, digested and identified by MALDI-TOF analysis (78).  
PKM1 and PKM2 Protein Expression and Western Blot Analysis 
Cells were washed twice with DPBS and lysed with M-PER (Pierce) 
supplemented with protease and phosphatase inhibitors. Protein concentrations were 
determined by the Pierce BCA protein assay kit (Thermo Fisher Scientific, Rockford, 
IL).  Prepared protein samples were loaded on a gel with a pre-stained, broad-range, 
molecular weight protein marker (Bio-Rad). Proteins were fractionated by 
electrophoresis using 10 % polyacrylamide gels. The gels were transferred by wet 
blotting onto PVDF membranes (Millipore, Bedford, MA). The membranes were 
blocked with 5 % skim milk in Tris-buffered saline with 1% Tween-20 (TBS-T) for 1 h 
with gentle shaking. Membranes were then incubated overnight with a specific primary 
antibody against PKM2 (1:1000), PKM1 (1:1000) and Actin (1:5000) at 4 °C. The 
membranes were washed four times with TBS-T and incubated for 1 h at room 
temperature with the secondary antibody conjugated with horseradish peroxidase (HRP) 
at 1:5000 dilution. Specific bands were developed using a SuperSignal West Femto 
enhanced chemiluminescence (ECL) Western blotting detection kit (Pierce, Thermo 
Fisher Scientific, Inc., Rockford, IL) and the signals were captured by Chemi Doc XRS 
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(Bio-Rad Laboratories, Hercules, CA). Bands were quantified using densitometry with 
ImageJ software (NIH, Bethesda, MD).   
Nuclear Fractionation  
Nuclear extracts were obtained using a Nuclear Extract Kit (Active Motif 40010) 
according to manufacturer’s recommendations. Briefly, cells were washed twice with 
ice-cold DPBS and collected by scraping in DPBS.  Cells were then pelleted and 
resuspended in hypotonic buffer. Next, detergent was added to the samples, and then 
these were centrifuged for 30 s at 14,000×g. The supernatant (cytoplasmic fraction) was 
removed and saved. The nuclear pellet was resuspended in complete lysis buffer and the 
nuclear protein fraction was collected after centrifugation for 10 s at 14,000×g. PKM2 
nuclear protein expression was analyzed by Western blot as described previously. 
PKM2 Crosslinking Analysis 
Cells were washed twice with ice-cold DPBS and collected by scraping in DPBS 
with 1× Complete Protease Inhibitor Mixture, EDTA-free (Roche Applied Science). 
Samples were incubated with 1 mM disuccinimidyl suberate (Thermo Scientific Pierce) 
for 30 min at room temperature. The reaction was quenched with the addition of 
1 M Tris, pH 7.5, to 30 mM final concentration and incubated for 10 min at room 
temperature. After quenching, cross-linked samples were lysed and protein 
concentrations were determined by the Pierce BCA protein assay kit (Thermo Fisher 
Scientific, Rockford, IL). Western blot analysis was used to analyze PKM2 crosslinked 
samples as described previously. 
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Pyruvate Kinase Activity Assay  
Pyruvate kinase activity was measured after cell lysates were directly exposed to 
mashua treatments and also in cells lysates that had been previously treated with mashua 
during their growth. For the first procedure, macrophages were plated at 1 ×105 
cells/well in 150 x 25 mm clear plates and cultured overnight. The cells were then 
stimulated by LPS for 19 h.  Cell lysates where exposed to mashua treatments and 
pyruvate kinase activity was measured. For the second procedure, macrophages were 
plated at 0.5×106 cells/well in 6-well plates (Costar) and cultured overnight. The cells 
were stimulated by LPS for 19 h either with or without 5 h-pre-treatment of mashua 
extracts. Pyruvate kinase activity in cell lysates was measured using the pyruvate kinase 
activity assay kit (BioVision, Mountain View, CA) according to the manufacturer’s 
instructions. Briefly, in this assay, phosphoenolpyruvate and ADP are converted into 
pyruvate and ATP by the reaction catalyzed by PK. Then, the generated pyruvate is 
oxidized by pyruvate oxidase to produce a color reaction (λ = 570 nm). The color 
intensity is proportional to the amount of pyruvate produced, and therefore the PK 
activity can be measured. Enzyme activity was normalized to total protein content in 
each sample  
Lactate Production Assay 
Macrophages were plated at 0.5×105 /well in a 96-well black and clear bottom 
plates (Costar) and cultured overnight. The cells were stimulated by LPS for 19 h either 
with or without 5 h-pre-treatment of mashua extracts as described above. Lactate 
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production in the medium was detected by using the Lactate Assay Kit (BioVision, 
Mountain View, CA), according to the manufacturer’s instructions. 
Total RNA Preparation and Real-Time qRT-PCR Analysis 
Total RNA was extracted from macrophages after LPS treatment for 6 or 19 h 
using the TRIzol® Reagent (Invitrogen, Carlsbad, CA), according to the manufacturer’s 
instructions. RNA concentration was measured with a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Willmington, DE). The 1 µg RNA, treated 
with DNase I to avoid DNA contamination, was reverse-transcribed into cDNA using the 
SuperScript III first-strand synthesis supermix (Invitrogen, Carlsbad, CA), following the 
manufacturers protocol. Finally, the cDNAs were used for real-time qRT-PCR analyses, 
which were performed using Power SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA), following the manufacturer’s instructions. cDNA 
amplification was carried out using a 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA). The primer sets are listed in Table 1 and were provided by 
Integrated DNA Technologies (IDT, Coralville, IA). The relative expression of each gene 
was normalized by β-Actin or by the geometrical mean of β-actin, GDHA and 18s 
ribosomal RNA (96), and was calculated following the comparative Ct method (ΔΔCt), 
also known as the 2- ΔΔCt method (97).  
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Table 1 Sequences of primers used in gene expression studies 
Primer Sequence 
TNFα-F 5’-ACTGGCAGAAGAGGCACTCC -3’ 
TNFα-R 5’-CGATCACCCCGAAGTTCA-3’ 
COX-2-F 5’-ACATCGATGTCATGGAACTG-3’ 
COX-2-R 5’-GGACACCCCTTCACATTATT-3’ 
IFN-β-F 5’-TCCAAGAAAGGACGAACATTCG-3’ 
IFN-β-R 5’-TGAGGACATCTCCCACGTCAA-3’ 
IL-1β-F 5’-GAGCACCTTCTTTTCCTTCATCT-3’ 
IL-1β-R 5’-GATATTCTGTCCATTGAGGTGGA-3’ 
iNOS-F 5’-GCTCGCTTTGCCACGGACGA-3’ 
iNOS-R 5’-AAGGCAGCGGGCACATGCAA-3’ 
β-Actin-F 5’-CCCAGGCATTGCTGACAGG-3’ 
β-Actin-R 5’-TGGAAGGTGGACAGTGAGGC-3’ 
PKM2-F 5’-TCGCATGCAGCACCTGATT-3 
PKM2-R 5’-CCTCGAATAGCTGCAAGTGGTA-3’ 
PKM1-F 5’-GCTGTTTGAAGAGCTTGTGC-3’ 
PKM1-R 5’-TTATAAGAGGCCTCCACGCT-3’ 
LDHA-F 5’-CTTCCTCAGTGTCCCATGTATC-3’ 
LDHA-R 5’-GTGTCTGCGCTCTTCTTCA-3’ 
PDK1-F 5’-CCACTGAGGAAGATCGACAGAC-3’ 
PDK1-R 5’-AGAGGCGTGATATGGGCAATCC-3’ 
GLUT1-F 5’-ATGGATCCCAGCAGCAAG-3’ 
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Statistical Analysis 
The data were analyzed using Student's t-test or one-way analysis of variance 
(ANOVA) followed by Tukey-HSD test, using the software JMP Pro v10.0. Results are 
expressed as means ± standard errors (SE) from at least three biological repeats. 
Different letters show significant differences (P < 0.05). 
Results 
Total Phenolic Content of Mashua Genotypes 
The total phenolic analysis indicated that the purple genotypes of mashua 
203003, 203021 and 203040 contained 390, 382.4 and 313.0 mg CAE/ mg of dried 
extract respectively. On the other hand, the yellow genotypes of mashua 203076, 203109 
and 203081 contained 58.4, 60.5 and 76.3 mg CAE/ mg of dried extract respectively. 
Overall, the purple genotypes of mashua contained higher phenolic content compare to 
the yellow genotypes.  
Table 1 Continued 
 
 
GLUT1-R 5’-CCAGTGTTATAGCCGAACTGC-3’ 
18S ribosomal RNA-F 5’-CTTAGAGGGACAAGTGGCG-3’ 
18S ribosomal RNA-R 5’-ACGCTGAGCCAGTCAGTGTA-3’ 
GDHA-F 5’-AATGTGTCCGTCGTGGATCT-3’ 
GDHA-R 5’-CATCGAAGGTGGAAGAGTGG-3’ 
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Characterization and Identification of Compounds by LC-MS in Mashua Extracts and 
Fractions 
Mashua 203040    
HPLC/MS profiles of mashua 203040 fractions F1, F2 and F3, are illustrated in 
Figure 4, and the profiles of fractions F4H2O and F4MeOH in Figure 5. The retention 
time, peak area, UV absorption, molecular weight, MS
2
, and identification of 
compounds detected in mashua 203040 fractions F1, F2, F3, F4H2O, and F4MeOH, are 
listed in Table 2-6, respectively. The compounds were identified according to their 
fragmentation data and UV absorption. In the ethyl acetate fraction (F1), compound 1 at 
R.T 15.95 with [M+H]
 +
 180 yielded in MS
2
 fragments at m/z 167, 149, 105, and 70.07, 
the major fragmentation of m/z 149 was due to the loss of benzyl isothiocyante group 
and this compound was assigned as 4-methoxy benzyl isothiocyanate. Compound 2 at 
R.T 23.70 showed UV maxima at 227, 278 with [M+H]
+
 166 yielded MS
2
 fragments at 
m/z 147 and 121, the major fragment 121 was due to the loss of 4-hydroxy vinyl cation. 
Compound 3 at R.T 26.08 showed UV maxima at 227, 278 with [M+H]
+
 150 yielded 
MS
2
 fragments at m/z 121 and 77, and this compound was identified as benzyl 
isothiocyanate. Compound 4 at R.T 31.60 with [M+H]
+
 206 yielded MS
2
 fragments at 
m/z 161, 149, 136, 118, and this compound was identified as indolemethyl-
isothiocyanate. Compound 5 at R.T 33.97 and compound 6 at R.T 37.11 with [M+H]
+
 
282 and [M+H]
+
 369 yielded MS
2 
fragments 150 and 121, and 262, respectively. 
Compound 5 was tentatively identified as indole methyl phenyl derivative and 
compound 6 remained unknown.  
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Figure 4 HPLC/MS profiles of mashua 203040 fractions F1, F2 and F3. 
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Figure 5 HPLC/MS profiles of mashua 203040 fractions F4 H2O and F4 MeOH. 
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Table 2 Identification of phytochemicals from the ethyl acetate fraction (F1) from 
mashua 203040 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
1 15.95 6021206.1 180 
227, 
278 
MS
2
 180 : 
167, 149, 
105, 70.07 
4-methoxy 
benzyl 
isothiocyanate 
2 23.70 1392619.6 166 
227, 
278 
MS
2
 166: 
147, 121 
4-hydroxy 
benzyl 
isothiocyanate 
3 26.08 11045159.9 150 
227, 
278 
MS
2
 150: 
121, 77.0 
benzyl 
isothiocyanate 
4 31.60 11274489.1 206 
227, 
278 
MS
2
 206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
5 33.97 13642787.9 282 
227, 
282 
MS
2
 282: 
150, 121 
unknown 
isothiocyante 
derivative 
6 37.11 3407525.6 369 
227, 
280 
MS
2
 : 369 
262 
unknown 
isothiocyante 
derivative 
7 44.50 1399933.5 579 
235, 
278 
MS
2
 : 579 
457, 288 
Procyanidin B2 
8 45.75 1564125.5 457 
235, 
275 
MS
2
 : 457 
457, 305, 
169 
(–)-
epigallocatechin 
gallate 
9 49.92 1642212.5 441 
232, 
261 
MS
2
 : 441 
289, 169 
epicatechin 
gallate 
10 55.35 4730827.4 165 310 
MS
2
 : 165 
127, 118 
p-Coumaric acid 
11 55.97 3799947.4 339 315 
MS
2
 : 339 
190.9, 
162.9, 172.9 
5-pCoQA (5-p-
coumaroylquinic 
acid) 
12 60.70 3315513.2 333 315 
MS
2
 : 333 
168, 150, 
124.8 
GCA (gallic-
caffeic acid 
ester) 
13 75.30 1218374 343 328 
MS
2
:343 
160.9,134.9 
202.8, 
280.9, 250.9 
diCA (dicaffeic 
acid) 
 
 38 
 
Table 3 Identification of phytochemicals from the acetone fraction (F2) from mashua 
203040 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
1a 32.45 2962101.5 773 
330, 
520 
MS
2
 773 : 
627, 303 
delphinidin 3-
sophoroside-5-
rhamnoside 
2a 34.55 2783552.6 465 
330, 
520 
MS
2
 465: 
465, 303 
delphinidin 3-
glucoside 
3a 36.02 1013766.6 611 
330, 
520 
MS
2
 150: 
465, 303 
delphinidin 3-
glucoside-5-
rhamnoside 
4a 38.65 3815699.9 757 
330, 
520 
MS
2
 757: 
611, 287 
cyanidin 3-
sophoroside-5-
rhamnoside 
5a 40.45 6225991.6 449 
330, 
520 
MS
2
 449: 
287 
cyanidin 3-
glucoside 
6a 41.11 3961601.8 595 
330, 
520 
MS
2
 595: 
287 
cyanidin 3-
rutinoside 
7a 42.32 
 
694663.7 
653 
330, 
520 
MS
2
 653: 
465, 303 
delphinidin 3-
glucoside-5-
acetylrhamnoside 
8a 44.41 2704222.1 815 
330, 
520 
MS
2
 815: 
627, 303 
delphinidin 3-
sophoroside-5-
acetylrhamnoside 
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Table 4 Identification of phytochemicals from the methanol fraction (F3) from mashua 
203040 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
1a 32.45 168954.9 773 
330, 
520 
MS
2
 773 : 
627, 303 
delphinidin 3-
sophoroside-5-
rhamnoside 
2a 34.55 55115.1 465 
330, 
520 
MS
2
 465: 
465, 303 
delphinidin 3-
glucoside 
3a 36.02 1489770.0 611 
330, 
520 
MS
2
 150: 
465, 303 
delphinidin 3-
glucoside-5-
rhamnoside 
4a 38.65 1897289.2 757 
330, 
520 
MS
2
 757: 
611, 287 
cyanidin 3-
sophoroside-5-
rhamnoside 
5a 40.45 216900.5 449 
330, 
520 
MS
2
 449: 
287 
cyanidin 3-
glucoside 
6a 41.11 1561713.1 595 
330, 
520 
MS
2
 595: 
287 
cyanidin 3-
rutinoside 
7a 42.32 196824.6 653 
330, 
520 
MS
2
 653: 
465, 303 
delphinidin 3-
glucoside-5-
acetylrhamnoside 
8a 44.41 160946.0 815 
330, 
520 
MS
2
 815: 
627, 303 
delphinidin 3-
sophoroside-5-
acetylrhamnoside 
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Table 5 Identification of phytochemicals from the fraction F4 H2O from mashua 203040 
 
Peak 
No 
Retentio
n time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
2 23.70 13753932.5 166 
227, 
278 
MS
2
 166: 
147, 121 
4-hydroxy 
benzyl 
isothiocyanate 
3 25.74 13477752.8 150 
227, 
278 
MS
2
 150: 
121, 77.0 
benzyl 
isothiocyanate 
4 31.54 53905704.4 66.44 206 
227, 
278 
MS
2
 206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
 
 
Table 6 Identification of phytochemicals from the fraction F4 MeOH from mashua 
203040 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
3 25.93 3901391.4 150 
227, 
278 
 
MS
2
 150: 
121, 77.0 
benzyl 
isothiocyanate 
4 31.54 2737010.5 206 
227, 
278 
MS
2
 206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
4b 33.09 34552575.2 317 
227, 
278 
MS
2
 316: 
136, 180 
N,N-Di(4-
methoxybenzyl
)thiourea 
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The compound 7 at R.T 44.5 with [M+H]
 +
 579 yielded in MS
2
 fragments at m/z 
457 and 288, which was identified as procyanidin B2. Compound 8 at R.T 45.75 with 
[M+H]
 +
 457 yielded in MS
2
 fragments at m/z 457, 305, 169, and this compound was 
identified as epigallocatechin gallate. Compound 9 at R.T 49.92 with with [M+H]
 +
 441 
yielded in MS
2
 fragments at m/z 289 and 169; this compound was identified as 
epicatechin gallate. Procyanidin B2, epigallocatechin gallate, epicatechin gallate, gallic 
acid and coumaric acid derivatives were previously identified by HPLC-DAD in 
Tropaeolum tuberosum Ruız & Pavon tubers (90). Compound 10 at R.T 55.35 with 
[M+H]
 +
 165 yielded in MS
2
 fragment at m/z 127 and 118, and this compound was 
identified as p-Coumaric acid. Compound 11 with [M+H]
 +
 339 yielded in MS
2
 fragment 
at m/z 190.9, 162.9, 172.9 and this compound was identified as 5-pCoQA (5-p-
coumaroylquinic acid). Compound 12 at R.T 60.70 gave [M+H]
+
 333 yielded MS
2
 
fragments 168, 150, 124.8 as this compound was assigned GCA (gallic-caffeic acid 
ester). Compound 13 at R.T 75.30 gave [M+H]
+
 343 yielded MS
2
 fragments 160.9, 
134.9, 202.8, 280.9, 250.9 as this compound was assigned as diCA (dicaffeic acid).  
HPLC, ESI/MS and MS-MS were used to characterize anthocyanins from the 
acetone (F2) and methanol (F3) fractions of mashua 203040 (98). Peaks 1a, 2a, 3a, 7a, 
and 8a showed m/z 303 as a major fragment, which indicate that the peaks contained 
delphinidin derivatives. Molecular ions at m/z 773 and 611 were observed in peaks 1a 
and 3a, which then were fragmented into two main molecular ion peaks at m/z 627 and 
303 and m/z 465 and 303, respectively. The observation of the molecular ions at m/z 627 
and 303 might have been attributed to the loss of a rhamnose molecule (146u) and a 
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sophorose molecule (321u), while the molecular ions at m/z 465 and 303 were generated 
by the loss of a rhamnose molecule (146u) and a glucose molecule (162u). Taking all the 
fragments into consideration, the molecules present in peaks 1a and 3a were identified 
as delphinidin 3-sophoroside-5-rhamnoside and delphinidin 3-glucoside-5-rhamnoside, 
respectively. Peak 2a was found to be delphinidin 3-glucoside since it showed a 
molecular ion at m/z 465 with a loss of 162u that is attributed to a glucose molecule. 
Peak 7a was found to be delphinidin 3-glucoside-5-acetylrhamnoside since it showed a 
molecular ion at m/z 653 and fragment ions at m/z 465 and 303 (99). The observation of 
the molecular fragments at m/z 465 and 303 might have been attributed to the loss of a 
rhamnose molecule linked to an acetyl group (146 + 42u) and the loss of a glucose 
molecule (162u), respectively. Peak 8a was found to be delphinidin 3-sophoroside-5-
acetylrhamnoside since it showed a molecular ion at m/z 815 and fragments at m/z 627 
and 303. The observation of the molecular fragments at m/z 627 and 303 might have 
been attributed to the loss of a rhamnose molecule linked to an acetyl group (146 + 42u) 
and the loss of a sophorose molecule (324u), respectively.  
Peaks 4a, 5a, and 6a showed m/z 303 as a major fragment, which indicate that 
the peaks contained cyanidin derivatives. Peak 4a was found to be cyanidin 3-
sophoroside-5-rhamnoside since it showed a molecular ion at m/z 757 and fragment ions 
at m/z 611 and 287. Peaks 5a and 6a were identified as cyaniding 3-glucoside and 
cyanidin 3-rutinoside since they showed molecular ions at m/z 449 and 595, respectively. 
The ion fragmentation can be attributed to the loss of a glucose molecule (162u) and a 
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rutinose molecule (308u). The anthocyanins identified in this study are in agreement 
with previously reported anthocyanins in Tropaeolum tuberosum (89). 
Fraction F4H2O is rich in isothiocyanates. The isothiocyanates detected are the 
same as in F1, but present in higher concentrations. Compound 4 was the major peak in 
this fraction and was identified as indolmethyl isothiocyanate. Compounds 2 and 3 were 
previously identified as 4-hydroxy benzyl isothiocyanate and benzyl isothiocyanate. In 
F4 MeOH, compound 4b at R.T 33.09 with [M+H]
+
 317 yielded MS
2
 fragments at m/z 
136 and 180 compound was identified as N,N-Di(4-methoxybenzyl)thiourea. This 
compound has been reported previously from glucosinolate-containing plants (100).  
Mashua 2013081 
HPLC/MS profiles of mashua 203081 fractions F1, F2 and F3, are illustrated in 
Figure 7, and the profiles of fractions F4H2O and F4MeOH in Figure 8. The retention 
time, peak area, molecular weight, MS
2
, and identification of the compounds detected in 
mashua 203081 fractions F1, F2, F3, F4H2O, and F4MeOH, are listed in Table 7-11 
respectively. The compounds were identified according to their fragmentation data and 
UV absorption. In the ethyl acetate fraction (F1), compound 1 at R.T 16.13 with [M+H]
 
+
 180 yielded in MS
2
 fragments at m/z 167, 149, 105 and 70.07 the major fragmentation 
of m/z 149 was due to the loss of benzyl isothiocyante group and this compound was 
assigned as 4-methoxy benzyl isothiocyanate.  
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Figure 6 HPLC/MS profiles of mashua 203081 fractions F1, F2 and F3. 
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Figure 7 HPLC/MS profiles of mashua 203081 fractions F4 H2O and F4 MeOH. 
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Table 7 Identification of phytochemicals from the ethyl acetate fraction (F1) of mashua 
203081 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
1 16.13 26205628.6 180 
227, 
278 
MS
2 
180 : 
167, 149, 
105, 105, 
70.07 
4-methoxy 
benzyl 
isothiocyanate 
2 23.43 23090689.4 166 
227, 
278 
MS
2 
166: 
147, 121 
4-hydroxy 
benzyl 
isothiocyanate 
3 28.57 24755101.9 150 
227, 
278 
MS
2 
150: 
121, 77.0 
benzyl 
isothiocyanate 
4 34.33 7200317 206 
227, 
278 
MS
2 
206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
5 39.27 3510478.7 282 
227, 
282 
MS
2 
282: 
150, 121 
unknown 
isothiocyante 
derivative 
6 41.18 6843253.8 369 
227, 
280 
MS
2
 369: 
262 
unknown 
isothiocyante 
derivative 
7b 44.96 10260012.3 611 
235, 
278 
MS
2
 611: 
345, 303, 
273, 257 
 
Rutin 
 
 
8b 49.44 15212413.0 491 
235, 
275 
MS
2 
491: 
481, 448, 
430, 426, 
403, 330, 
294, 272 
 
CQA-
derivative 
9a 50.61 3450294.1 503 
232, 
261 
MS
2
 503: 
356, 382, 
427, 447 
CQA-
derivative 
10a 51.83 3510714.3 330 
245, 
263, 
346, 
382 
MS
2 
330: 
330, 311, 165 
quercetin 
dimethyl ether 
11a 54.62 5618018.0 195 
243, 
283 
MS
2
 195: 
135, 161 
Ferulic  
amide 
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Table 7 Continued 
12a 57.22 4889549.8 528 333 
MS
2
 528: 
202, 184.8 , 
178 
QQCA 
(quinicquinic- 
caffeic acid 
ester) 
13a 69.35 
 
2095980.7 
333 328 
MS
2
 333: 
172.9 , 
160.9,136.9 
5-FQA (5-O-
feruloylquinic 
acid) 
14a 71.66 2138591.8 343 328 
MS
2
 343: 
160.9, 134.9 
202.8, 280.9, 
250.9 
diCA 
(dicaffeic acid) 
 
Table 8 Identification of phytochemicals from the acetone fraction (F2) from mashua 
203081 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
1b 35.42 1496857.1 576 
231, 
249 
MS
2
 576: 
557, 543, 
502, 418, 
310, 292, 
257 
Not identified 
Tentative 
structure 
Isothiocyanate 
derivative 
2b 38.83 3653480.9 644 
232, 
261 
MS
2
 644: 
624, 595, 
552, 521, 
479, 436, 
270 
Not identified 
Tentative 
structure 
Isothiocyanate 
derivative 
3b 41.25 9243666.0 545 
230, 
264 
MS
2
 545: 
484 
Not identified 
Isothiocyanate 
derivative 
4c 43.34 4402690.8 467 
230, 
265 
MS
2
 467:  
154 
Not identified 
Isothiocyanate 
derivative 
5b 44.24 62259.6 467 
230, 
265 
MS
2
 467: 
154 
Not identified 
Isothiocyanate 
derivative 
6b 48.81 39616.8 467 
230, 
265 
MS
2
 467:  
154 
Not identified 
Isothiocyanate 
derivative 
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Table 9 Identification of phytochemicals from the methanol fraction (F3) from mashua 
203081 
 
Peak 
No 
Retention 
time 
Area 
Mass 
[M+H] 
UV MS
n
 Identification 
1b 35.28 3150626.8 576 
231, 
249 
MS
2
 576: 
557, 543, 
502, 418, 
310, 292, 
257 
Not identified 
Tentative 
structure 
Isothiocyanate 
derivative 
2b 38.68 325949.8 644 
232, 
261 
MS
2
 644: 
624, 595, 
552, 521, 
479, 436, 
270 
Not identified 
Tentative 
structure 
Isothiocyanate 
derivative 
3b 41.15 568060.7 545 
230, 
264 
MS
2
 545: 
484 
Not identified 
Isothiocyanate 
derivative 
4c 42.60 312758.3 467 
230, 
265 
MS
2
 467:  
154 
Not identified 
Isothiocyanate 
derivative 
 
 
Table 10 Identification of phytochemicals from the fraction F4 H2O from mashua 
203081 
 
Peak 
No 
Retention 
time 
 
Area 
Mass 
[M+H]+ 
 
UV 
 
MS
n
 Identification 
2 20.81 42911183.9 166 
227, 
278 
MS
2 
166: 
147, 121 
4-hydroxy 
benzyl 
isothiocyanate 
3 25.87 16923893.6 150 
227, 
278 
MS
2 
150: 
121, 77.0 
benzyl 
isothiocyanate 
4 31.89 46084341.9 206 
227, 
278 
MS
2 
206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
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Table 11 Identification of phytochemicals from the fraction F4 MeOH from mashua 
203081 
 
Peak 
No 
Retentio
n time 
 
Area 
Mass 
[M+H] 
 
UV 
 
MS
n
 Identification 
3 25.99 5728017.6 150 
227, 
278 
MS
2 
150: 
121, 77.0 
benzyl 
isothiocyanate 
4 30.30 2504390.1 206 
227, 
278 
MS
2 
206: 
161, 149, 
136, 118 
Indolemethyl-
isothiocyanate 
4b 33.67 38391967.3 317 
227, 
278 
MS
2  
316: 
136, 180 
N,N-Di(4-
methoxybenzyl) 
thiourea 
 
 
 
 
Compound 2 at R.T 23.43 showed UV maxima at 227, 278 with [M+H]
+
 166 
yielded MS
2
 fragments at m/z 147 and 121,  the major fragment 121 was due to the loss 
of 4-hydroxy vinyl cation. Compound 3 at R.T 28.57 showed UV maxima at 227, 278 
with [M+H]
+
 150 yielded MS
2
 fragments at m/z 121 and 77, and this compound was 
identified as benzyl isothiocyanate. Compound 4 at R.T 34.33 with [M+H]
+
 206 yielded 
MS
2
 fragments at m/z 161, 149, 136, 118, and this compound was identified as 
indolemethyl-isothiocyanate. Compound 5 at R.T 39.27 and compound 6 at R.T 41.18 
with [M+H]
+
 282 and [M+H]
+
 369 yielded MS
2 
fragments 150 and 121, and 262, 
respectively. Compound 5 was tentatively identified as indole methyl phenyl derivative 
and compound 6 remained unknown. Here for the first time we have determined the 
presence of isothiocyanates by MS fragmentation pattern. Some of the isothiocyantes 
like 4-methoxy benzyl isothiocyanate and benzyl isothiocyante were previously reported 
in Tropaeolum tubersom (101).  
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Figure 8 illustrates the structures of identified isothiocyantes in mashua 203040 
and 203081. The compound 7b at R.T 44.96 with [M+H]
+
 611 yielded in MS
2
 fragments 
at m/z 345, 303, 273, 257, 245, 180, the major fragmentation of m/z 303 was due to the 
loss of quercetin group. Compound 7b was identified as rutin. The compound 8b at R.T 
49.44  with [M+H]
+
491 yielded in MS
2
 fragments at m/z 481, 448, 430, 426, 403, 330, 
294, 272, the major fragmentation of m/z 355 can be assigned to chlorogenic acid 
fragment. The m/z 456 can be explained on the basis of the loss of the 2 hydroxy groups 
as shown in the structure (Figure 9A). There were no relevant reports of this molecule, 
however a closely related structure of chlorogenic acid derivative have been reported as 
a cosmetic, which show skin-conditioning effect (102). The compound 9a at R.T 50.61 
with [M+H]
+
 503 yielded in MS
2
 fragments at m/z 355, 382, 427 and 447 the major 
fragmentation of m/z 356 can be assigned to chlorogenic acid fragment. The m/z 382 can 
be explained on the basis of the loss of the carbonyl group which accounts the loss of 28 
Da in the structure (Figure 9B). There were no relevant reports of this molecule however 
a closely related structure of chlorogenic acid derivative have been reported as an Itk 
(interleukin-2 inducible T-cell kinase), a Th2-cell target, isolated from the Australian 
rainforest tree Polysciasmurrayi (103). Compounds 10a at R.T 51.83 and 11a at R.T 
54.62 were reported as quercetin dimethyl ether and ferulicamide based on the 
fragmentation and the UV pattern from the literature (104). Compound 12a at R.T 57.22 
gave [M+H]+ 528 yielded MS
2
 fragments 202, 184.8, 178 and this compound was 
assigned as QQCA (quinicquinic- caffeic acid).   
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Figure 8 Structures of identified isothiocyantes in mashua 203040 and 203081. 
 
 
4-methoxy benzyl 
isothiocyanate 
1 
4-hydroxy benzyl 
isothiocyanate 
2 
benzyl 
isothiocyanate 
3 
indolemethyl-
isothiocyanate 
4 
unknown isothiocyante 
derivative 
5 
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Figure 9 Tentative structures of the chlorogenic acid derivative from the ethylacetate 
extract (F1) in mashua 203081. 
 
 
 
 
 
8b 
9a 
A 
B 
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Compound 13a at R.T 69.35 gave [M+H]
+
 333 yielded MS
2
 fragments 172.9, 
160.9, 136.9 as this compound was assigned 5-FQA (5-O-feruloylquinicacid). 
Compound 14a at R.T 71.66 gave [M+H]
+
 343 yielded MS
2
 fragments 160.9, 134.9 
202.8, 280.9, 250.9 as this compound was assigned as diCA (dicaffeic acid). For 
fractions F2 and F3, the peak 1b at 35.42 (m/z 576) gave MS
2
 fragments at 557, 543, 
502, 418, 310, 292, 257, peak 2b at 38.83 (m/z 644) gave MS
2
 fragments at 643, 624, 
595, 552, 521, 479, 436, 270, peak 3b at 41.25 (m/z 545) gave MS
2
 fragment at 484 and 
peak 4c, 5b and 6b gave same (m/z 467) MS
2
 fragment at 466, 154. There were no 
reports for these molecules however from the knowledge of the types of molecules 
formed in mashua and the high molecular weight these fragments obtained could be 
justified and constructed as shown in Figure 10.  
Fraction F4H2O is rich in isothiocyantes. The isothiocyanates detected are the 
same as in fraction F1, but present in higher concentrations. Compound 4 was the major 
peak in this fraction and was identified as indolmethyl isothiocyanate. Compounds 2 and 
3 were previously identified as 4-hydroxy benzyl isothiocyanate and benzyl 
isothiocyanate. In fraction F4 MeOH, compound 4b at R.T 33.09 with [M+H]
+
 317 
yielded MS
2
 fragments at m/z 136 and 180 compound was identified as N,N-Di(4-
methoxybenzyl)thiourea.  
Effect of Mashua Extracts on LPS-Induced ROS and NO productions  
Here we assessed the effect of six mashua extracts on NO and ROS production in 
LPS-stimulated RAW 264.7 macrophage cell line.  
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Figure 10 Tentative structures of isothiocyanates from acetone (F2) and methanol (F3) 
extracts in mashua 203081. 
 
 
 
 
 
 
 
 
1b 2b 
3b 4c 
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The MTS assay showed that 100 µg/ml extract dose did not affect cell viability 
(Figure 11A), and therefore this concentration was used for the following experiments. 
The effects of mashua extracts on LPS-induced NO were investigated using Griess 
reagent on the extracellular medium. All mashua extracts suppressed NO levels (Figure 
11B). The extracts of genotypes 203081 and 203040 showed the greatest reduction of 
NO levels. When LPS-induced ROS production was assessed using DCFA at 19 h after 
the LPS challenge, all genotypes, except for genotype 203076, suppressed ROS 
production (Figure 11C). The extracts of genotypes 203040 and 203003 showed the 
greatest reduction on ROS levels. Among all mashua genotypes extracts, 203081 and 
203040 were among the most active extracts to reduce both NO and ROS production and 
thus were selected fort further study of their molecular targets. 
Identification of PKM as a Potential Target of Mashua Extracts  
DARTS strategy was used to identify the cell-targets of mashua extracts 203081 
and 203040. DARTS, revealed a strong protected band near 60 kDa in the mashua 
203081 (Figure 12A) and 203040 (Figure 12B) treated samples. In gel-digestion and 
MALDI-TOF analysis identified the protected band as pyruvate kinase, muscle (PKM). 
There are two isoforms of PKM, PKM1 and PKM2. Western blotting detection 
confirmed that mashua extracts could protect PKM1 and PKM2 from proteolysis 
induced by pronase treatment (Figure 12C), indicating binding to these proteins. To 
validate the biological relevance of the binding of mashua phytochemicals to PKM, we 
next assessed the effect of mashua extracts 203081 and 203040 on pyruvate kinase 
activity.  
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Figure 11 Effect of mashua extracts on cell viability and LPS-induced NO and ROS 
production. (A) Effect of mashua extracts on cell viability in macrophage cells. RAW 
264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) were treated with 100 µg/ml 
mashua extract for 24 h and then the cell viability was measured by MTS assay.  (B-C) 
Effect of mashua extracts on LPS-induced NO and ROS production. RAW264.7 cells 
(0.5×10
5
 cells/well in 96-well culture plates) were pretreated with 100 µg/ml mashua 
extract for 5 h and then stimulated with LPS (1 µg/ml) for 19 h. Griess reagent was used 
to detect the generation of extracellular nitrite (B) and DCFA was used to determine the 
generation of intracellular ROS at 19 h after the LPS challenge (C). Data, obtained from 
four biological repeats at least, are shown as mean ± SE values. Different letters indicate 
significant differences by the ANOVA/Tukey-HSD (p < 0.05).  
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Figure 12 Identification of PKM as a potential target of mashua phytochemicals in 
RAW264.7 macrophages by DARTS methodology. (A-B) RAW 264.7 cell lysates were 
incubated with 400 µg/ml of mashua extract 203081 (A) and 203040 (B) for 3 h at RT, 
and then digested with pronase for 25 min at RT, followed by Silver or Coomassie blue 
staining. Black arrow indicates a strong band (~60 kDa) protection from pronase 
proteolysis by both mashua extracts. In gel-digestion and MALDI-TOF analysis 
identified the protected band as pyruvate kinase, muscle (PKM). (C) The protective 
effects of mashua extracts on PKM1 and PKM2 proteolysis were confirmed by western 
blot analysis using DARTS lysates. (D) Pyruvate kinase activity was measured in 
RAW264.7 cell lysates that where directly exposed to mashua treatments, using the 
pyruvate kinase activity assay kit according to the manufacturer’s instructions. Data, 
obtained from three biological repeats at least, are shown as mean ± SE values. Different 
letters indicate significant differences by the ANOVA/Tukey-HSD (p < 0.05). Symbols 
indicate significant differences by Student’s t test (#p < 0.1,*p < 0.05).  
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Pyruvate kinase activity was measured in cell lysates that were directly exposed 
to mashua treatments. Results showed that extract 203040 significantly (p<0.05) 
inhibited PK activity at 50, 100 and 200 µg/ml while extract 203081 inhibited only at 
100 and 200 µg/ml. Overall extract 203040 was a more potent inhibitor of PK activity 
(Figure 12D). 
Effects of Mashua Extracts on LPS- Induced Pyruvate Kinase Activity and Lactate 
Production  
To further study PKM as target of mashua phytochemicals we next evaluated the 
effect of 19 h LPS stimulation in RAW 264.7 macrophages on pyruvate kinase activity 
and lactate production and the effect of mashua extracts on both markers. Pyruvate 
kinase was measured in cell lysates that had been treated with mashua during their 
growth. Results showed that there is a slight increase in PKM activity after cells were 
stimulated by LPS for 19 h. Extract 203040 at 100 µg/ml significantly inhibited PKM 
activity to levels comparable to the negative control. Extract 203081 also inhibited PKM 
activity, but at a lower extent (Figure 13A). Lactate is the end product of non-oxidative 
glycolysis and is produced from pyruvate in a reaction catalyzed by lactate 
dehydrogenase (LDH). Since PKM is involved in the production of pyruvate, lactate 
levels will be influenced by PKM activity rate. Results show that there is a significant 
increment in lactate levels after cells were stimulated by LPS for 19 h. Both extracts 
significantly inhibited the LPS-induced lactate production at 50 and 100 µg/ml (Figure 
13B). 
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Figure 13 Effect of mashua extracts on LPS-induced lactate production and pyruvate 
kinase and mitochondrial dehydrogenase activity. (A) Effect of mashua extracts on 
pyruvate kinase activity. RAW264.7 cells (0.5×10
6
 cells/well in 6-well culture plates) 
were pretreated with 100 µg/ml mashua extract for 5 h and then stimulated with LPS (1 
µg/ml) for 19 h. Pyruvate kinase activity was measured using the pyruvate kinase 
activity assay kit according to the manufacturer’s instructions. (B) Effect of mashua 
extracts on lactate production and (C) mitochondrial dehydrogenase activity. RAW264.7 
cells (0.5×10
5
 cells/well in 96-well culture plates) were pretreated with 100 µg/ml 
mashua extract for 5 h and then stimulated with LPS (1 µg/ml) for 19 h. Lactate 
production in the medium was detected by using the Lactate Assay Kit, and 
mitochondrial dehydrogenase activity was evaluated using the MTS assay kit according 
to the manufacturer’s instructions. Data, obtained from three biological repeats at least, 
are shown as mean ± SE values. Different letters indicate significant differences by the 
ANOVA/Tukey-HSD (p < 0.05). Symbols indicate significant differences by Student’s t 
test (#p < 0.1).  
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Effects of Mashua Extracts on LPS-Induced Mitochondrial Dehydrogenase Activity  
The effect of mashua extracts 203081 and 203040 on LPS-induced mitochondrial 
dehydrogenase activity was evaluated using the MTS assay kit. In the MTS assay, 
tetrazolium is mainly reduced to formazan by intracellular NADH.  
Some reports agree that, despite the mitochondrial NADH contribute to the reduction 
of tetrazolium, the formation of formazan depends primarily on the rate of glycolytic 
NADH production (105, 106). Results show that 19 h after LPS stimulation, formazan 
levels increased significantly when compared to the control and this effect was 
significantly reduced with both mashua extracts (Figure 13C). When macrophages are 
stimulated with LPS the rate of glycolysis increases whereas the rate of respiration 
decreases, and this phenomena is part of what is known as the Warburg effect (19). 
Therefore the increment in formazan levels upon LPS stimulations is likely a reflection 
of the increment in NADH produced in glycolysis, in addition to mitochondrial NADPH.  
Effects of Mashua Extracts on LPS-Induced ROS Production in Early and Late 
Inflammatory Response  
The effect of different doses of mashua 203081 and 203040 extracts on LPS-
induced ROS production in early (6 h after LPS challenge) (Figure 14A) and late (at 19 
h after LPS challenge) (Figure 14B) inflammatory response, was examined by 2′,7′-
Dichlorofluorescin diacetate (DCFA). At 6 and 19 h after LPS stimulation, both extracts 
at doses of 25, 50 and 100 µg/ul suppressed LPS-induced ROS. The reductions of ROS 
by both mashua extracts was higher at 6 h compared to 19 h.  
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Figure 14 Effect of mashua extracts on LPS-induced ROS production in early and late 
inflammatory response. RAW264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) 
were pretreated with 100 µg/ml mashua extract for 5 h and then stimulated with LPS (1 
µg/ml) for 6 h or 19 h. DCFA was used to determine the generation of intracellular ROS 
at 6 h (A) and 19 h (B) after the LPS challenge. Data obtained from a minimum of four 
biological repeats are shown as mean ± SE values. Different letters indicate significant 
differences by the ANOVA/Tukey-HSD (p < 0.05).  
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Mashua extract 203040 at concentrations of 25, 50 and 100 µg/ul reduced ROS 
by 29.77, 38.78 and 50.60 % respectively at 6 h after LPS challenge and by 22.67, 28.20 
and 27.10 %, respectively at 19 h after LPS challenge. On the other hand, mashua extract 
203081 at concentrations of 25, 50 and 100 µg/ul reduced ROS by 30.89, 35.21 and 
50.47 %, respectively at 6 h after LPS challenge and by 21.69, 35.95 and 31.44 %, 
respectively at 19 h after LPS challenge. 
Effects of Mashua Extracts on ROS Dependent LPS-Induced Gene Expressions in 
Early and Late Inflammatory Response 
The effects of mashua extracts 203081 and 203040 on various pro-inflammatory 
gene expressions at 6 h (Figure 15A) and 19 h (Figure 15B) after LPS-stimulation were 
examined by real-time qRT-PCR analysis. Results show that LPS at 6 h promotes the 
expression of IL-1β, TNFα and iNOS and at 19 h the expression of COX-2, IL-1β, TNFα, 
iNOS and IFN-β. As shown in Figure 15B, both mashua extracts at a concentration of 
100 µg/ml suppressed LPS-induced expressions of COX-2, IL-1β and iNOS at 19 h. 
Mashua extract 203040 suppressed the expression of IFN-β at 19 h. Both extracts 
enhanced LPS-induced expression of TNFα at 19 h.  Furthermore, the effect of both 
mashua extracts on LPS-induced expressions of IL-1β, iNOS and TNFα were examined 
at 6 h (Figure 15A). Results show that mashua extracts 203081 and 203040 at 
concentration of 100 µg/ml were able to significantly suppress the expressions of IL-1β 
and iNOS at 6 h. Mashua extract 203081 suppressed the expression of TNFα at 6 h.  
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Figure 15 Effects of mashua extracts on ROS dependent LPS-induced gene expressions 
in early and late inflammatory response. RAW 264.7 cells (0.5×10
6
 cells/well in 6-well 
culture plates) were pretreated with 100 µg/ml mashua extract for 5 h and then 
stimulated with LPS (1 µg/ml) for 6 h (A) or 19 h (B). Subsequently, total RNAs were 
prepared and subjected to real-time qRT-PCR analysis using specific primer sets, 
responsible for TNFα, COX-2, IFN-β, IL-1 β and iNOS genes. β-actin was used as the 
reference gene. Data obtained from triplicate repeats are shown as mean ± SE. Different 
letters indicate significant differences by the ANOVA/Tukey-HSD (p < 0.05).  
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ROS plays an important role in the activation of transcription factors such as NF-
κB and AP-1 and therefore in the expression of genes regulated by these transcription 
factors (31, 32, 107). In previous work done in our lab, we showed that different genes 
respond differently to the suppression of ROS levels, some being more sensitive than 
others (Bang and Cisneros-Zevallos, Unpublished). This could explain why some genes 
(COX-2, IL-1β, iNOS and IFN-β) were suppressed at 19 h while others (TNFα) required 
a higher inhibition of ROS and were only suppressed at 6 h.   
Effects of Mashua Extracts on PKM1, PKM2 and PKM2 Codependent Gene 
Expression in Late Inflammatory Response 
The effect of mashua extracts 203081 and 203040 on the expression of PKM1, 
PKM2 and genes co-activated by PKM2, including PDK1, GLUT1 and LDHA were 
evaluated at 6 h (Figure 16A) and 19 h (Figure 16B) after LPS-stimulation by real-time 
qRT-PCR analysis. Results show that LPS stimulation for 19 h, promoted the gene 
expression of GLUT1, while the expression of PKM2, PKM1 and LDHA remained the 
same when compared to the control. The expression of PDK1 decreased with LPS at 19 
h when compared to the control. Both mashua extracts reduced significantly LPS-
induced GLUT1expression at 19 h. For PKM1, PKM2, LDHA and PDK1, neither 
mashua extract had an effect on gene expression levels compared to the LPS control.  
Furthermore, results show that LPS stimulation for 6 h, did not affect the expression of 
GLUT1 and PKM1, and reduced the expression of PKM2, PDK1 and LDHA.  
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Figure 16 Effects of mashua extracts on PKM1, PKM2 and PKM2 codependent gene 
expression in early and late inflammatory response. RAW 264.7 cells (0.5×106 
cells/well in 6-well culture plates) were pretreated with 100 µg/ml mashua extract for 5 h 
and then stimulated with LPS (1 µg/ml) for 6 h (A) or 19 h (B). Subsequently, total 
RNAs were prepared and subjected to real-time qRT-PCR analysis using specific primer 
sets, responsible for PKM1, PKM2, PDK1, LDHA, and GLUT1 genes. For 6h, β-actin 
was used as the reference gene. For 19h, the geometrical mean of three reference genes 
(β-actin, GDHA and 18s ribosomal RNA), was used. Data obtained from triplicate 
repeats are shown as mean ± SE. Different letters indicate significant differences by the 
ANOVA/Tukey-HSD (p < 0.05).  
 
 66 
 
Neither mashua extract had an effect on gene expression levels compared to the 
LPS control. In general, this group of genes shows very low expression levels, and 
therefore variations in the reference gene can significantly affect these results (96). For 
this reason, for the genes analyzed at19 h after LPS-stimulation, the geometrical mean of 
three reference genes (β-actin, GDHA and 18s ribosomal RNA) was used to analyze the 
expression of these genes. For the genes analyzed at 6 h after LPS-stimulation only β-
actin was use as the reference gene. 
The Effect of LPS on PKM1 and PKM2 Protein Expression and PKM2 Conformation 
and Nuclear Translocation  
The effects of LPS stimulation for 19 h on PKM1and PKM2 protein expression 
was investigated by western blot analysis.  Results show that PKM2 protein levels 
remain the same after 19 h stimulation with LPS, while PKM1 expression significantly 
increases (Figure 17A). PKM2 can switch between a tetramer, a monomer, and a dimer, 
and can be located in the cytoplasm or in the nucleus.  The location and conformation of 
PKM2 can define its function (83) and thus this was studied. The effect of 19 h LPS 
stimulation on nuclear PKM2 levels was evaluated by using a Nuclear Extract Kit 
(Active Motif 40010) and western blot analysis. Results show that there is not a 
significant change in the nuclear PKM2 protein levels upon LPS stimulation for 19 h. 
Moreover, neither mashua extract had an effect on the nuclear PKM2 protein levels 
(Figure 17B). To understand how LPS stimulation affects PKM2 conformation, 
croslinking analysis was performed (Figure 18).  
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Figure 17 The effect of LPS on PKM1 and PKM2 total protein expression, and PKM2 
nuclear protein expression. RAW 264.7 cells (0.5 × 106 cells/well in 6-well culture 
plates) were pretreated with 100 µg/ml mashua extract for 5 h and then stimulated with 
LPS (1 µg/ml) for 19 h. (A) For PKM1 and PKM2 protein expression, cell lysates were 
subjected to SDS-PAGE and Western blot analysis using specific antibodies against 
PKM1, PKM2 and B-actin. (B) For nuclear PKM2, nuclear fractions were isolated as 
described under Materials and Methods and subjected to SDS-PAGE and Western blot 
analysis using specific antibodies against PKM2 and NPM. The protein bands in the 
upper panels were detected by chemiluminescence. The histograms in the bottom panels 
represent the relative protein levels measured by ImageJ software. Data, obtained from 
at least three biological repeats, are shown as the mean ± SE. Different letters indicate 
significant differences by the ANOVA/Tukey-HSD (p < 0.05). Asterisks indicate 
significant differences by Student’s t test (p < 0.05). 
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Figure 18 The effect of LPS on PKM2 conformation. RAW 264.7 cells (0.5 × 10
6
 
cells/well in 6-well culture plates) stimulated with LPS (1 µg/ml) for 19 h. For PKM2 
configuration study cells were crosslinked with with 1 mM disuccinimidyl suberate as 
described in Material and Methods. Cell lysates were subjected to SDS-PAGE and 
Western blot analysis using specific antibodies against PKM2 and β-actin. The protein 
bands in the upper panel were detected by chemiluminescence. The histograms in the 
bottom panel represent the relative protein levels measured by ImageJ software. Data, 
obtained from at least three biological repeats, are shown as the mean ± SE. Asterisks 
indicate significant differences by Student’s t test (p < 0.05). 
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Results show that PKM2 is mainly present as a monomer in RAW264.7 cells, 
and upon LPS stimulation the monomeric form significantly decreases. Moreover, a 
tetramer, trimer and dimer forms of PKM2 were also detected. The dimeric form of 
PKM2 was shown to increase with LPS at 19 h, while no significant changes were 
detected with the tetramer and trimer. 
Effect of Mashua Fractions on LPS-Induced ROS and NO Production and 
Assessment of Binding to PKM2 
In order to understand the identity of the mashua phytochemicals that possess  
anti-inflammatory properties, mashua 202040 and 203081 fractions (F1, F2, F3, F4, 
F4MeOH and F4H2O) were evaluated for their effects on the LPS-induced 
inflammation. The MTS assay confirmed that neither 50 and 100 µg/ml doses of all 
fractions affected the cell survival rate more than 20%, except for 100 µg/ml F3 and 100 
µg/ml F4H20 of mashua 203081 (Figure 19A) and 100 µg/ml F4H20 of mashua 203040 
(Figure 20A), which were not used for the following experiments. Fractions F1 (100 
µg/ml) and F3 (50 and 100 µg/ml) from mashua extract 203040 showed the highest 
effect on the suppression of NO (Figure 20B) and ROS (Figure 20C) at 19 h, while all 
the other fractions showed little or no effect. On the other hand, fractions F2 (100 µg/ml) 
and F3 (50 µg/ml) from mashua extract 203081 showed the highest effect on 
suppression of NO (Figure 19B) and ROS (Figure 19C) at 19 h, while all the other 
fractions showed little or no effect. Furthermore, we evaluated the binding of the 
fractions to PKM2 using DARTS strategy.  
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Figure 19 Effect of mashua 203081 fractions on cell viability and LPS-induced NO and 
ROS production. (A) Effect of mashua extracts on cell viability in macrophage cells. 
RAW 264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) were treated with 50 or 
100 µg/ml mashua fractions for 24 h and then the cell viability was measured by MTS 
assay.  (B-C) Effect of mashua fractions on LPS-induced NO and ROS production. 
RAW264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) were pretreated with 50 or 
100 µg/ml mashua fractions for 5 h and then stimulated with LPS (1 µg/ml) for 19 h. 
Griess reagent was used to detect the generation of extracellular nitrite (B) and DCFA 
was used to determine the generation of intracellular ROS at 19 h after the LPS 
challenge (C). Data, obtained from four biological repeats at least, are shown as mean ± 
SE values. Different letters indicate significant differences by the ANOVA/Tukey-HSD 
(p < 0.05). 
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Figure 20 Effect of mashua 203040 fractions on cell viability and LPS-induced NO and 
ROS production. (A) Effect of mashua extracts on cell viability in macrophage cells. 
RAW 264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) were treated with 50 or 
100 µg/ml mashua fractions for 24 h and then the cell viability was measured by MTS 
assay.  (B-C) Effect of mashua fractions on LPS-induced NO and ROS production. 
RAW264.7 cells (0.5×10
5
 cells/well in 96-well culture plates) were pretreated with 50 or 
100 µg/ml mashua fractions for 5 h and then stimulated with LPS (1 µg/ml) for 19 h. 
Griess reagent was used to detect the generation of extracellular nitrite (B) and DCFA 
was used to determine the generation of intracellular ROS at 19 h after the LPS 
challenge (C). Data, obtained from four biological repeats at least, are shown as mean ± 
SE values. Different letters indicate significant differences by the ANOVA/Tukey-HSD 
(p < 0.05). 
 72 
 
For mashua 203081 only fraction F3 protected PKM2 from proteolysis when 
compared to the control (Figure 21A) indicating that the phytochemicals present in this 
fraction are binding PMK2. Instead, for mashua 203040 fractions F1, F2 and F3 
protected PKM2 from proteolysis when compared to the control (Figure 21B) indicating 
that phytochemicals present in F1, F2 and F3 are binding PMK2. 
Discussion  
Chronic inflammation can lead to the development of different conditions 
including diabetes, arteriosclerosis and some types of cancers (8-11). Macrophages play 
a key role in chronic inflammation and therefore have been used as a model in drug 
discovery studies associated with inflammation and related conditions. Dietary 
phytochemicals have been extensively studied in the past years for their health beneficial 
properties. Despite the promising results, the cellular targets of most dietary 
phytochemicals have not been yet reported. The lack of understanding of the mechanism 
of action of most dietary compounds limits their potential use as medicinal foods, 
supplements or drugs, and their regulation.  In this study, we were able to overcome this 
barrier and could demonstrate that phytochemicals from two genotypes of mashua 
reduce LPS-induced inflammation in RAW264.7 macrophages by targeting PKM and 
reducing ROS. Moreover, we proposed a Warburg-like effect in the RAW264.7 
macrophage cell line.  
M1 or classically activated macrophages, besides energy, have a high demand for 
biosynthetic precursors used for synthesis of pro-inflammatory proteins. 
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Figure 21 Assessment of binding of mashua fractions to PKM2 by DARTS 
methodology. RAW 264.7 cell lysates were incubated with 400 µg/ml of mashua 203081 
(A) and 203040 (B) fractions for 3 h at room temperature, and then proteolized with 
pronase for 25 min at room temperature. DARTS cell lysates were subjected to SDS-
PAGE and Western blot analysis using specific antibodies against PKM2 and β-actin. 
The protein bands in the upper panel were detected by chemiluminescence. The 
histograms in the bottom panel represent the relative protein levels measured by ImageJ 
software. Data, obtained from three biological repeats, are shown as the mean ± SE. 
Asterisks indicate significant differences by Student’s t test (p < 0.05). 
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In order to meet these new needs, M1 macrophages exhibit an increase in aerobic 
glycolysis and a decrease in oxidative phosphorylation, known as the Warburg effect. 
Recently, different studies have highlighted the importance of the Warburg effect in the 
activation of M1 macrophages. Thus, targeting key mediators of the Warburg effect has 
been proposed as a promising therapeutic approach to modify inflammatory responses 
(6, 19). An important mediator of the Warburg effect is pyruvate kinase M2 (PKM2), a 
protein kinase and transcriptional coactivator. PKM catalyzes the last step of glycolysis, 
which is the conversion of phosphoenolpyruvate (PEP) to pyruvate with the production 
of one molecule of ATP. There are two isoforms of PKM, PKMI and PKM2, which are 
produced by alternative splicing of the PKM gene (108, 109). The PKM1 isoform is 
always present as an active tetramer while the PKM2 isoform can be regulated 
allosterically or by posttranslational modifications, which allows it to switch between an 
active tetramer and a less active monomer/dimer (108). In undifferentiated primary 
macrophages, PKM2 increases upon the stimulation with LPS and plays an important 
role in the Warburg effect and inflammatory response. Thus, PKM2 has been proposed 
as a target for inflammation (83, 110).   
In our study, we used the secondary RAW264.7 macrophage cell line as a model 
of inflammation.  We report that LPS stimulation in this particular cell line induces 
several changes that are in agreement with previous reports of the Warburg effect in 
macrophages, as well as characteristics that are not. Thus, we proposed that LPS 
stimulation in RAW264.7 macrophages induce a Warburg-like effect (111). We found 
that the basal PKM2 protein level in this cell line is high, and that LPS stimulation did 
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not increase this level any further. In contrast, we found that PKM1 protein levels 
increase with LPS. Moreover, the nuclear PKM2, which is associated with a co-
transcription factor function, did not change with LPS stimulation.  
PKM2 together with the hypoxia-inducible factor (HF1) regulate various genes 
involved in the Warburg effect as well as in the inflammation response, including 
LDHA, PDK1, IL-1β and GLUT1 (19). The HIF1 heterodimer is formed by HIF1α and 
HIF1β. The HIF1β subunit is constitutively expressed in cells, while the expression of 
the HIF1α may be induced by a number of pathways, and its stability is highly 
dependent on O2 levels (112). HF1α plays a key role in gene regulation under hypoxic 
conditions. However, it has been reported that other stimuli like LPS, can also increase 
HF1α expression level and activity (113, 114).  
We observed that upon LPS stimulation in RAW264.7 macrophages, the 
expression of IL-1β increased at 6 and 19 h and the expression of GLUT1 at 19 h but not 
at 6 h.  This is in agreement with the fact that PKM2 is present in the nucleus, even 
before LPS stimulation, and that HF1α has been reported to increase with LPS. The 
expression of GLUT1 seems to be a late time response since it increases only at 19 h 
after LPS stimulation. It is likely that the HIF-1α levels required to promote the 
expression of GLUT1 are only reached at later times. ROS can promote the stabilization 
(33, 115) and enhance the transcription (116) of HIF-1α. Since ROS production in LPS 
stimulated macrophages increases with time, the levels of active HIF-1α will be higher at 
later times as well. IL-1β  besides HF1α is also regulated by AP-1 (117). The expression 
of PKM2, LDHA did not changed, while PDK1 decreased with LPS. It is possible that 
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these genes are less sensitive to HF1or that other signaling proteins are required for their 
expression. 
The up-regulation of GLUT1 gene expression is associated with an increased 
influx of glucose and glycolysis rate (118). The MTS results support these facts by 
showing that formazan levels, which are mainly associated with glycolytic NADH 
production (105, 106), increase with LPS. Also, we reported that the PKM activity 
increases, which is in agreement with the increased rate of glycolysis. Our results 
showed that PKM1 but not PKM2 increases with LPS, which indicates that PKM1 is 
responsible for the increment in PKM activity. PKM2 monomeric form decreases with 
LPS, but its dimeric form increases. It is possible that the dimeric form exerts a higher 
enzymatic activity, which can be attributed to the increment in PKM activity as well.  
Moreover, our results indicate that upon LPS stimulation lactate levels increase. Overall, 
we show that GLUT1 gene expression increases, which translates into a higher influx of 
glucose and higher glycolysis rates. Additionally, part of the pyruvate produced will be 
converted to lactate. 
In our report, we showed that mashua phytochemicals exert their anti-
inflammatory properties by interfering with the NF-κB pathway and attenuating the 
Warburg-like effect possibly by the suppression of ROS and inhibition of PKM activity. 
The model showing the mechanism of action of mashua in RAW 264.7 is illustrated in 
Figure 22.  
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Figure 22 Anti-inflammatory role of mashua extracts. 
 
 
Macrophage cells produce high levels of ROS after the LPS challenge through 
the NADPH oxidase and the mitochondria electron transfer chain (28, 119). The ROS 
induced by LPS has shown to mediate the LPS/TLR4 signaling pathway through 
different ROS-responsive signaling proteins. For instance, ROS have been reported to 
mediate the LPS-induced activation of NF-κB through redox mechanisms (31, 32). NF-
κB can induce the expression of genes such as TNFa, COX-2, IFN-β (17), and eventually 
iNOS (26, 27).  We showed that mashua phytochemicals reduced ROS levels at 6 and 19 
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h and consequently were able to reduce the expression of TNFa, COX-2, IFN-β, and 
iNOS.  TNFa was the only gene that was only suppressed at 6 h but not at 19 h. In 
previous work done in our lab, we showed that different genes respond differently to the 
suppression of ROS levels, some being more sensitive than others (Bang and Cisneros-
Zevallos, Unpublished). The reduction of ROS by both mashua extracts was higher at 6 
h compared to 19 h. This could explain why some genes (COX-2, IL-1β, iNOS and IFN-
β) were suppressed at 19 h while others (TNFα) required a higher inhibition of ROS and 
were only suppressed at 6 h.  Additionally, the reduction of NO at 19 h could be 
explained by the reduction of iNOS, which is the enzyme responsible for its synthesis.  
Furthermore, ROS can promote the stabilization and enhance the transcription of 
Hif-1α (33, 115). Therefore the suppression of ROS by mashua extracts can reduce the 
transcription and stability of Hif-1α, and consequently decrease the expression of some 
of the genes regulated by this transcription factor. Mashua reduced the expression of IL-
1β and GLUT1. The down regulation of GLUT-1 is associated with a lower influx of 
glucose and glycolysis rate (118). Thus, the mashua extracts can suppress the LPS-
induced glycolysis. The MTS results support this finding by showing that mashua 
suppress the LPS induced formazan levels, which are mainly associated with glycolytic 
NADH production (105, 106). Moreover, it has been reported that increasing glucose 
uptake by GLUT1 is sufficient to promote a M1 macrophage phenotype, highlighting the 
importance of this transporter in the Warburg effect and inflammatory response (118) 
In addition mashua exerts its anti-inflammatory properties by binding and 
inhibiting the activity of PKM. PKM2 has been widely studied for its role in cancer and 
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recently it has emerged as an important target for inflammation (83, 84).  In the Warbug-
like effect in LPS stimulated RAW264.7, we show that not only PKM2, but PKM1 also 
plays an important role in the Warburg effect and the respective inflammatory response. 
In the present study, we found that the phytochemicals of mashua exerted anti-
inflammatory properties partially by inhibiting the activity of PKM and consequently 
reducing lactate production. In agreement with our results, a previous report showed that 
the PKM2 inhibitor shikonin protected mice against lethal endotoxic shock and sepsis by 
inhibiting PKM2 activity, lactate production, and HMGB1 release (84). It has been 
shown that lactate can further promote the inflammation processes by  stimulating Toll-
like receptor (TLR)-4 signaling activation in macrophages (120). In addition, lactate 
promotes macrophage activation via an autocrine HMGB1-dependent pathway (121). 
Therefore, mashua can exert its anti-inflammatory properties in part through lactate 
suppression caused by the inhibition of PKM activity.  
In order to identify the phytochemicals from mashua that possess the anti-
inflammatory properties, mashua extracts were fractionated, and these fractions were 
evaluated for their ability to reduce LPS-induced ROS and NO in macrophages, and to 
bind to PKM2. The phytochemicals responsible for ROS and NO reduction seem to be 
present mainly in F3 for mashua 203081, which contains isothiocyanate derivatives. This 
fraction contains a major compound (1b), tentatively identified as an isothiocyanate 
derivative, which may be responsible for the bioactivity of this fraction. However, 
further studies should be conducted to elucidate the structure of this compound. Instead, 
for mashua 203040, the phytochemicals responsible for ROS and NO reduction seem to 
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be present mainly in F1 and F3, which contain isothiocyanates and phenolics, and 
anthocyanins, respectively. Both isothiocyanates and anthocyanins have been shown to 
have anti-inflammatory and anti- oxidant properties (122-124). PKM2 but not PKM1 has 
been reported to play an important role in cancer and in M1 macrophage polarization. 
Thus, using DARTS methodology, we evaluated the mashua fractions that bind to 
PKM2. The phytochemicals responsible for the inhibition of PKM2 seem to be present 
mainly in F3 for 203081, which mostly contain isothiocyanate derivatives. Instead for 
mashua 203040 the compounds in F1, F2 and F3, which correspond to both phenolics 
and isothiocyanates seem to be responsible for the inhibition of PKM2. In a recent report 
phenolics have been reported to inhibit PKM2 activity (34), however to our knowledge 
this is first time isothiocyanates are reported to bind to PKM2.  
In conclusion we evaluated the anti-inflammatory properties of mashua extracts 
and we identify PKM as a potential target of its phytochemicals through the use of 
DARTS methodology.  However, further studies should be done to confirm the binding 
of mashua to PKM. In, additional studies should be conducted to confirm that mashua 
exerts its anti-inflammatory properties by binding and inhibiting the activity of PKM and 
not through interfering in other steps of PKM regulation. We also showed that mashua 
extracts exert their anti-inflammatory properties and attenuate the Warburg effect by 
suppressing ROS levels and consequently interfering with different ROS-responsive 
signaling proteins. Finally we showed that the bioactive compounds in mashua are both 
phenolics and isothiocyanates.   
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CHAPTER III                                                                                                   
IDENTIFICATION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS FROM 
ACEROLA (MALPIGHIA EMARGINATA) USING A COMBINED ASSAY-GUIDED 
FRACTIONATION AND DRUG AFFINITY RESPONSIVE TARGET STABILITY 
(DARTS) METHODS 
 
Overview 
The leaves of acerola (Malpighia emarginata) have shown to have anti-
inflammatory properties and to inhibit prostaglandin production in macrophages. The 
objective of this study was to identify the bioactive compounds acting as COX-2 
inhibitors in acerola leaf extracts using bioassay-guided fractionation and DARTS 
methodology. The leaf extract (F4) was fractionated using solid-phase extraction with 
C18 cartridges into three fractions (F1, F2 and F3). The leaf extract and fractions 2 and 3 
inhibited (P<0.05) COX-2 activity. LC-MS and NMR analysis revealed that F3 contains 
a major compound with glycerol/glycolipid/sphingolipid type structure which could be 
responsible for the COX-2 inhibitory properties of this fraction. F2 showed the highest 
COX-2 inhibitory effect among the fractions, and also showed binding to COX-2 by 
DARTS methodology and therefore its fractions (F2A, F2B, and F2C) were further 
tested for their ability to bind and inhibit COX-2 activity. All subfractions inhibited 
COX-2 activity but only F2C showed binding by DARTS after 25 min of pronase 
digestion. However, after 10 min of pronase digestion F2A and F2C showed binding by 
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DARTS, possibly indicating that the phytochemicals from F2A bind reversibly to COX-
2, whereas the ones from F2C bind irreversibly. GC-MS profiling revealed F2A contains 
alkenes while F2B contains terpenes, which could account for the COX-2 inhibitory 
properties of these sufractions. LC-MS and GC-MS profiling revealed that F2C contains 
flavonoids and small amounts of terpenes. F2C was further fractionated into F2C1, 
F2C2, F2C3 and F2C4. Interestingly, only fraction F2C4 with aliphatic triterpene like 
compounds inhibited COX-2 activity. These results indicate that compounds with 
glycolipid/sphingolipid type structures, terpenes and alkenes are possibly responsible for 
the COX-2 inhibitory properties of acerola leaves.  
Introduction  
Over the years, many bioactive extracts and compounds from natural resources 
have been used for the development of new drugs, nutraceuticals or functional foods. 
The identification of bioactive extracts and compounds should ideally include the 
elucidation of cellular targets and associated pathways where these exert their activity. 
However, most studies have focused on the phenotypic changes, in the cell or organism, 
induced by a compound or an extract, instead of focusing on the identification of specific 
proteins targeted by these compounds. The reasoning behind this deficit is mostly due to 
the technical difficulty of finding appropriate methods to elucidate molecular targets. 
There are numerous target identification techniques described to date; however, affinity 
chromatography has been the most widely used method for target identification (69, 70). 
In affinity chromatographic purification, proteins from a cell lysate or tissue homogenate 
are incubated with an affinity matrix conjugated with the bioactive compound followed 
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by eluting the bound proteins and resolving them by electrophoresis on an SDS-PAGE 
gel. Subsequently, the purified target proteins can be identified by peptide 
microsequencing or, most commonly, by modern degradative mass spectrometric 
techniques (125). Despite the technological advances, affinity-based target identification 
techniques continue to be limited due to the necessity of derivatization of the small 
molecules without losing their bioactivity (72). For instance, conjugation to affinity 
matrices (a covalent attachment of target compounds to a polymeric solid support) can 
induce chemical and structural changes of the bioactive compound leading to the loss of 
native properties of the compound (125). Recently, it was reported that DARTS, drug 
affinity responsive target stability, methodology can identify the direct binding of 
compounds to protein targets, without requiring any chemical modification of the 
compound. The DARTS approach is based on the concept that small molecules can 
stabilize the structure of their target proteins and result in protease resistance. DARTS is 
unique in that the small molecules are used without the need for chemical derivatization 
or even knowing the chemical identity or purity of the compound (72, 74, 78). 
Bioassay-guided fractionation has been frequently used in the discovery of 
bioactive compounds. In this approach, fractions generated from an extract are tested for 
their ability to induce desirable biochemical or cellular responses; the fractions giving a 
positive test are further processed until the bioactive compounds are isolated (126). One 
of the major limitations of using bioassay guided fractionation is that bioactive 
compound search is restricted to the availability of the bioassays; many potential protein 
targets like receptors, enzymes, kinases, transcription factors and others might not have 
 84 
 
available assays associated to them or these assays might be hard to implement. One 
possible way to overcome this limitation is the use of the DARTS methods applied to 
screening, thus compounds binding to specific target molecules could potentially be 
identified. 
Malphigia emaprginata, commonly known as “acerola”, is a fruit-bearing small 
evergreen tree that belongs to the Malpighiaceae family. Acerola is indigenous to the 
Lesser Antilles, Central America, and northern parts of South America, but nowadays it 
is cultivated globally. Brazil is one of the largest producers of acerola in the world (127). 
Acerola fruit is well known for its high Vitamin C content that can range from 695- 4827 
mg/100 g of raw fruit  (128). Studies on the phytochemical composition of acerola fruit 
have indicated the presence of anthocyaninins, flavonols, phenolic acids (129), and 
carotenoids (130). The fruit of acerola has been shown to possess antioxidant, anti 
hyperglycaemic (131), anti-inflammatory (132), anti-cancer, and antimicrobial activities 
(133). Despite the numerous reports on acerola fruits, there is only one study done on the 
chemistry of acerola leaf (134). Recently, our group characterized the phenolics and 
non-polar compounds from acerola leaf and reported the anti-inflammatory properties of 
acerola leaf extract and fractions for the first time (Bang et al., Unpublished). Moreover, 
we reported that phytochemicals from the leaves of acerola are able to reduce 
significantly LPS- induced prostaglandin levels in RAW264.7 macrophages 
(Unpublished).  
The objective of this study was to identify the bioactive compounds from acerola 
extracts using bioassay-guided fractionation and DARTS methodology. Since our 
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previous work showed that acerola leaf extracts inhibited prostaglandin production in 
macrophage cells, we specifically focused in the present study on elucidating the 
bioactive compounds acting as COX-2 inhibitors. In addition, DARTS was evaluated as 
a screening method by the parallel comparison of the results obtained by bioassay 
fractionation using a commercial COX-2 kit.  
In this study we present a proof of concept by which using a combined classical 
bioassay guided fractionation targeting COX-2 activity is confirmed simultaneously by 
COX-2 binding using the DARTS method. 
Materials and Methods  
Freeze dried acerola leaves of the genotype BRS-238 were supplied by 
EMPRAPA, Fortaleza, Brazil. Upon arrival at Texas A&M University, the samples were 
frozen and kept at −80 °C until use. The following chemicals were used in the 
experiments: Lipopolysaccharide (LPS), Dulbecco’s Modified Eagle’s Medium 
(DMEM)/low glucose, penicillin/streptomicyn mixture, DMSO and Fetal Bovine Serum 
(FBS) were purchased from Sigma (St. Louis, MO). Glucose and sodium bicarbonate 
were purchased from Acros Organics (Fair Lawn, NJ) and sodium bicarbonate from 
Mallinckrodt Chemicals (Phillipsburg, NJ), respectively. COX Inhibitor Screening 
Assay Kit was purchased from Cayman (Ann Arbor, MI). M-PER mammalian protein 
extraction reagent and Halt phosphatase inhibitor cocktail were purchased from Thermo 
Scientific (Rockford, IL). Protease inhibitor cocktail tablets and pronase were purchased 
from Roche Diagnostics (Indianapolis, IN). Antibodies against COX-2 and β-Actin were 
purchased from Cell Signaling Technology (Danvers, MA). Macrophages RAW 264.7 
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(cell line TIB-71™) were acquired from the American Type Culture Collection (ATCC) 
(Manassas, VA).  
Crude extract (F4) preparation 
A 1 g aliquot of the lyophilized acerola leaf powder was dissolved in MeOH and 
stirred at 4°C for 24 h. The extract was centrifuged and concentrated at 4000 rpm 
(2147g) and 45 °C until all of the volatile solvents were evaporated in a Centrivap 
concentrator connected to a cold trap (Labconco, Kansas City, MO).  
TLC Analysis, Fractionation (Fractions F3 – F1) and Subfractionation (F2A, F2B, 
F2C) 
The acerola leaf fractions or subfractions were spotted on a TLC plate to 
determine the possible presence of terpenoids using the Liebermann Burchard test and 
anisaldehyde/sulphuric acid spray reagent  (135). The crude extract (F4) was 
fractionated using solid-phase extraction with C18 cartridges by a modified procedure 
previously reported (136). A schematic representation of the flow chart showing the 
elution of the fraction with different solvents is illustrated in Figure 23. Briefly, the 
crude extract (F4) (849 mg) was dissolved in minimum amount of MeOH/H2O solution 
(1ml) and then adjusted to pH 7.0 with 5 N NaOH. A total of 1 mL of extract was loaded 
in SEP Pack C18 cartridge (55–105 μm, Waters Corp., Milford, MA, USA) previously 
conditioned to pH 7.0 with 20 mL of 100% methanol and 50 mL of nanopure water (pH 
7.0).  The neutral phenolics and other compounds were absorbed in the cartridge, while 
the phenolic acids were not. The cartridge was washed with 50 mL of water (pH 7.0).  
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Figure 23 Extraction, fractionation and subfractionation scheme used for acerola leaves.  
 
 
The water from the wash containing the phenolic acids that were not absorbed in 
the cartridge was adjusted to pH 2.0. This mixture was loaded into a second cartridge 
previously conditioned at pH 2.0 with 50 mL of methanol and 50 mL of nanopure water 
at pH 2.0. Phenolic acids bound to the matrix of the second cartridge were later eluted 
with 50 mL of methanol (F1). Subsequently, the compounds in the first cartridge were 
eluted with 50 mL of MeOH and with 50 mL of ethyl acetate to obtain fractions F2 and 
F3, respectively. All the fractions (F1 (61.2 mg) , F2 (481 mg) and F3 (131 mg) were 
eluted with low boiling point solvents and were completely evaporated at 45°C using a 
 88 
 
speed vac (Labconco, Kansas City, MO). Fraction F2 (481 mg) was further fractionated 
as shown in Figure 23.  Briefly, fraction 2 was subjected to Silica gel chromatography 
(10 × 200 cm, 80 g) eluted with 150 ml of hexane, 150 ml dichloromethane and 150 ml 
methanol in increasing polarity to obtain fractions F2A (20 mg), F2B (82 mg), F2C (215 
mg), respectively. 
Fractionation of F2C by Reverse Phase HPLC  
F2C (215mg) was dissolved in 5ml MeOH, 1 ml of the extract was pipetted out 
and filled in each 1 ml HPLC vial (43 mg/ml). This extract was then injected in the 
waters 515 series machine equipped with 996 PDA detector, and a semi preparative 
phenomenex -C18 column (10 × 250 mm, 5 μm)  for reverse phase HPLC analysis. The 
eluents were acetonitrile/methanol (1:1), formic acid (0.5:99.5, v/v) (phase A) and 
formic acid–water (0.5:99.5, v/v) (phase B). The applied elution conditions were: 0-2 
min, 0% A, 100% B; 3-5 min, 10%A, 90% B, 5-10 min, 20% A, 80% B; 10-20 min, 
35% A, 65% B; 20-30 min, 45% A, 55% B – 65% A, 35% B over period of 10 min; 31-
40 min 70% A, 30% B - 100 % A over the period of 10 min; 40-44 min was held 
isocratic, 100% A; 45-50 min 0% A, 100 % to the starting condition at 25°C at a flow 
rate of 2.0mL/min. Extracts were repeatedly injected (each time 100 ul of the extract) in 
the HPLC and the fractions were collected with the help of fraction collector (ISCO, 
Lincoln, NE) over the period of time 0-10 min (F2C1) 15 mg, 10-20 min (F2C2) 13 mg, 
20-30 min (F2C3) 21 mg  and 30-45 min (F2C4) 12 mg (Figure 23). The HPLC 
chromatogram of F2C is illustrated in Figure 24. 
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Figure 24 HPLC chromatogram of fraction F2C 
 
 
Chromatography and HPLC Conditions for Compound Isolation from F3 
Column chromatography was performed with silica gel (200−400 mesh, Alfa 
Aesar Ltd.) and reversed-phase C18 silica gel (250 mesh, Merck). Precoated TLC sheets 
of silica gel 60 GF254 (Silicycle Co., Ltd.) were used. Normal phase chromatography 
was done by Si column Astec, Advance science technologies (10 × 250 mm, 5 μm). The 
solvent system was composed of solvent A (hexane), solvent B (IPA) in the gradient 0-2 
min, 0% A, 100% B; 3-5 min, 95%A, 5% B, 5-20 min, 80% A, 20% B; 21-28 min, 65% 
A, 35% B; 28-30 min, 20% A, 80% B ; 31-33 min 10% A, 90% B; 34-36 min was held 
isocratic, 100% B; 36-37 min 100% A to the starting condition and was held for 3 more 
minutes with 100 % A at 25°C at a flow rate of 2 mL/min. The concentration of the 
extract (F3) was 10 mg/ml and was injected (30 ul) in the HPLC repeatedly till all 
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volumes were used up. These conditions were used to isolate the glycolipid compound 
from fraction 3.  
LC-MS Analysis and Conditions for Phenolics and Compound Isolation from F2 
The LC-MS system used is a Surveyor (Thermo Scientific, USA) coupled to 
Surveyor DAD. The eluents were acetonitrile/methanol (1:1), formic acid (0.5:99.5, v/v) 
(phase A) and formic acid–water (0.5:99.5, v/v) (phase B). The applied elution 
conditions were: 0-2 min, 2% A, 98% B; 3-5 min, 5%A, 95% B, 5-30 min, 20% A, 80% 
B; 30-72min, 35% A, 65% B; 72-83 min, 100% A, 0% B; 83-85 min was held isocratic, 
100% A; 87-90 min 2% A, 98% to the starting condition. The chromatograms were 
monitored at 330, 280, 210 nm; and complete spectral data were recorded in the range 
200–600 nm. A reversed-phase Phenomenex (Torrance, USA) Luna C18 column (150 
mm×4.6 mm i.d. and particle size 3 µm) with a Waters Nova-Pack C18 guard column (10 
mm×3.9 mm i.d, 4 µm) was used and a flow of 200 µL/min from the DAD eluent was 
directed to the ESI interface using a flow-splitter. Nitrogen was used as desolvation gas 
at 275◦C and a flow rate of 60 L/h, and no cone gas was used. Mass spectra were 
obtained on a MS Finnigan LCQ Deca XP Max,  Ion trap mass spectrometer coupled at 
the exit of the diode array detector and equipped with a Z-spray ESI source, and run by 
Xcalibur version 1.3 software (Thermofinnigan-Surveyor, San José, USA). A potential of 
1.5 kV was used on the capillary for negative ion mode. The source block temperature 
was held at 250 ◦C. These conditions were used for the characterization of phenolic 
compounds and for the isolation of three phenolic peaks from the extract of acerola leaf.  
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GCMS Conditions 
GC-MS was performed on Ultra GC/DSQ (ThermoElectron, Waltham, 
MA). Rxi-5ms was used as a gas chromatographic column with dimensions of 60 m 
length, 0.25 mm i.d., and 0.25 μm film thickness (Restek; Bellefonte, PA).  Helium was 
used as a carrier gas at constant flow of 1.5 ml/min.  Split (1:50) injections were 
used.  Transfer line and ion source were held at 250°C.  The column temperature was 
maintained at 50°C for 5 min and raised to 320°C at 20°C/min.  Mass spectra 
were acquired in full scan mode in the range of 30-500 m/z. 
NMR Specstroscopy 
 
1H and 13C NMR spectra were recorded on a Bruker Avance II 500 spectrometer 
operating at 500.130 MHz for 1H and at 125.758 MHz for 13C, and using a gradient-
equipped inverse 5 mm triple probe with p/2 pulses of 6.5, and 14.5 ms, respectively. 
The standard Bruker Topspin 2.1 software under Windows 7.0 was used throughout. A 
total of 2mg of the pure compound was dissolved in deuterated solvent. All experiments 
were performed at 22 uC in deuterated solvents. Scifinder we used to search the 
structures. 
Cell Culture  
Raw 264.7 macrophages were grown in the DMEM-low glucose (pH 7.2 – 7.4) 
including 4 g/l glucose, 3.7 g/l sodium bicarbonate, 10% fetal bovine serum (FBS) and 
antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) in a humidified 
atmosphere with 5% CO2 at 37°C. Cells were used at a passage of 3 to 8 in this study.  
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DARTS  
The target identification using drug affinity responsive target stability (DARTS) 
methodology was based on the protocol by Lomenick et al. 2011. Macrophages were 
plated at 2 ×10
6
 cells/well in 150 x 25 mm clear plates and cultured overnight. LPS (1 
µg/ml) was added for 24 h. Cells were washed twice with DPBS and then lysed with M-
PER (Pierce) supplemented with protease and phosphatase inhibitors. Protein 
concentrations were determined by the Pierce BCA protein assay kit (Thermo Fisher 
Scientific, Rockford, IL). Lysates were incubated with 400 μg/ml of acerola leaf extract 
(F4), fraction 2 and subfractions (F2A, F2B and F2C) or DMSO (control) for 3 h at 
room temperature.  Each sample was then divided into two aliquots, each of which 
underwent proteolysis with pronase or mock proteolysis, for 25 or 10 min at room 
temperature. A 1:1000 ratio of pronase versus cell lysates protein concentration was used 
for proteolysis. Proteolysis was stopped by addition of loading buffer (950 µl 2X 
laemmli buffer + 50 µl β-mercaptoethanol) to each sample at a ratio of 1:1 followed by 
western blot analysis.  
Western Blot  
A volume of 20 µl containing 15-20 µg of non-digested protein was loaded in 
each well of a 10 % polyacrylamide gel. The same volume (20 µl) was used for digested 
proteins. The gels were transferred by wet blotting onto PVDF membranes (Millipore, 
Bedford, MA). The membranes were blocked with 5 % skim milk in Tris-buffered saline 
with 1% Tween-20 (TBS-T) for 1 h with gentle shaking. Membranes were then 
incubated overnight with a specific primary antibody against COX-2 (1:1000) and Actin 
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(1:5000) at 4 °C. The membranes were washed four times with TBS-T and incubated for 
1 h at room temperature with the secondary antibody conjugated with horseradish 
peroxidase (HRP) at 1:5000 dilution. Specific bands were developed using a 
SuperSignal West Femto enhanced chemiluminescence (ECL) Western blotting 
detection kit (Pierce, Thermo Fisher Scientific, Inc., Rockford, IL) and the signals were 
captured by Chemi Doc XRS (Bio-Rad Laboratories, Hercules, CA). Bands were 
quantified using densitometry with Image J software (NIH, Bethesda, MD). 
COX-2 Inhibitory Assay  
The COX-2 inhibitory assay was carried out using the COX Inhibitor Screening 
Assay Kit following the manufacturer's instructions (Cayman Chemical, Ann Arbor, 
MI). Briefly, 10 µl of heme and 10 µl COX-2 (human recombinant) enzyme were added 
to test tubes containing 160 µl COX reaction buffer. The mixture was vortexed and 
exposed to either 200 µg/ ml acerola compounds or to 0.5% DMSO (control) for 10 min 
at 37 °C. This was followed by the addition of 10 µl arachidonic acid with further 
incubation for 2 min. Finally, 10 µl of hydrochloric acid (1 M) was added to stop the 
COX reaction followed by the addition of 20 µl stannous chloride (SnCl2) solution. This 
assay measures PGE2α derived from SnCl2 reduction of PGH2 produced in the COX-2 
reaction, by an enzyme immunoassay kit. 
Statistics Analysis 
The data were analyzed using Student's t-test or one-way analysis of variance 
(ANOVA) followed by Tukey-HSD test, using the software JMP pro v10.0. Results are 
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expressed as means ± standard errors (SE) from at least three biological repeats. . 
Different letters show significant differences (P < 0.05). 
Results  
Structure Elucidation of Compounds from Acerola Leaf Fractions by NMR Analysis 
In a previous experiment done by our lab (Bang et al., Unpublished), flavonoids 
from acerola leaf extract (F4) were characterized by HPLC-MS chromatography and 
MS/MS fragmentation (as shown in Appendix A) indicating mainly the presence of 
quercetin and kaempferol O-glycosides. The identified compounds (1 to 11), and 
additional data are shown in Appendix B. Additionally, GC-MS analysis demostrated the 
presence of terpenes, alkenes and lipidic compounds.  The GC-MS chromatogram of F4 
is shown in Appendix C and the identified compounds are shown in Appendix D. 
Following the fractionation scheme of the previous report, acerola leaf extract 
(F4) was fractionated into fractions F1, F2, and F3. The HPLC-MS chromatograms of 
these fractions are illustrated in Appendix E. In this study, compound 5, which was 
found to be present in F4 and F2, was further characterized using HRESIMS and 2D 
NMR. The molecular formula of compound 5 was determined as C31H36O19 on the basis 
of HRESIMS m/z 711.1851 [M-H]
-
 (calcd. m/z 711.6061 [M-H]
-
) and ESI-MS m/z 713 
[M+H]+. The IR spectrum showed the characteristic absorption bands of hydroxyl (3250 
cm
−1
), carbonyl (1665 cm
−1
), and phenyl groups (1576 cm
−1
). Fragmentation of 711[M-
H]
-
 by the MS/MS gave fragment [M-H-132]
-
 579 indicating a loss of a pentose sugar, 
followed by [M-H-132-162]
-
 417+42 [ACN adduct] 459 indicating that the second sugar 
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was a hexose and finally gave a fragment at m/z 285 [M-H-132-162-132]
-
 indicating that 
the second pentose sugar is attached to the kaempferol ring (Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 MS/MS fragmentation of compound 5  
 
 
The structural information concerning the attachment position of aforementioned 
moieties was determined based on MS fragmentation and 2D-NMR analysis. Further 
confirmation of the structure is explained by NMR analysis below and data is shown in 
Table 12. The aromatic region of the 
1
H-NMR spectrum of compound 5 showed four 
signals, namely, two broad singlets (δ 6.19 and δ 6.40) for the protons in ring A and two 
doublets (AA'BB' system) for ring B (δ 6.89 and δ 8.13, both with J = 8.6 Hz), which are 
typical for a kaempferol aglycone (137).  
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Table 12 NMR data of compound 5 
 
Position 
1
HNMR
a
 
13
CNMR
b
 HSQC 
1
H-
1
H 
COSY 
HMBC 
2 - 158.5 Cq - - 
3 - 134.9 Cq - - 
4 - 179.7 Cq - - 
4a - 158.4 Cq - - 
5 - 161.5 Cq - - 
6 6.19 (d, J = 
2.5) 
99.8 CH - 7, 8, 5, 4a 
7 - 165.9 Cq -  
8 6.40 (d, J = 
2.5) 
94.8 CH - 6, 7, 8, 8a, 
4a 
8a - 109.5 Cq -  
1´ - 122.9 Cq -  
2´ 8.13 (d, J = 
2.6) 
132.3 CH 2´, 6´ 3´, 1´, 6´, 4´ 
3´ 6.89 (d, J = 
8.9) 
116.3 CH 2´, 5´ 1´, 2´, 4´, 5´ 
4´ - 163.1 Cq -  
5´ 6.89 (d, J = 
8.6) 
116.3 CH 3´, 6´ 1´, 2´, 4´, 5´ 
6´ 8.13 (d, J = 
2.6) 
132.3 Cq 2´, 5´ 3´, 1´, 6´, 4´ 
Ara-O-3      
1´´ 5.34 (d, J = 
7.8) 
101.2 CH 2´´ 3, 2´´, 3´´, 
4´´ 
2´´ 3.93 (dd, J = 
3.5, 1.5) 
76.9 CH 1´´, 3´´ 1´´´, 2´´, 3´´, 
4´´ 
3´´ 3.65 (dd, J = 
1.5, 3.5) 
75.5 CH 2´´, 4´´ 1´´, 2´´, 4´´, 
5´´ 
4´´ 3.78 (dd, J = 
3.5, 1.5) 
70.8 CH 3´´, 5´´ 2´´, 3´´, 1´´, 
5´´ 
5a´´ 3.68 (dd, J = 
7.8, 3.5) 
66.9 CH2 4´´ 1´´´, 4´´, 3´´ 
5b´´ 3.17     
Api-O-      
1´´´ 5.45 (d, J = 
1.5) 
110.9 CH 2´´´ 2´´, 2´´´, 
3´´´, 4´´´ 
2´´´ 4.05 (d, J = 
1.5) 
75.2 CH 1´´´, 3´´´ 1´´´, 3´´´, 
4´´´, 5´´´ 
3´´´ - 80.8 Cq -  
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Table 12 Continued 
4´´´ 3.62-3.64 (d, 
J = 7.8) 
75.1 CH2 - 1´´´, 2´´´, 
3´´´, 5´´´ 
5´´´ 3.61 (s) 68.5 CH2 - 2´´´, 3´´´, 
4´´´ 
Glu-Ara      
1´´´´ 4.01 (d, J = 
7.8) 
104.5 CH 2´´´´ 2´´´´, 3´´´´, 
5´´´´ 
2´´´´ 3.10 (dd, J = 
7.8, 9.5) 
74.0 CH 1´´´´, 3´´´´ 1´´´´, 3´´´´, 
4´´´´ 
3´´´´ 3.65 (dd, J = 
7.5, 9.5) 
69.5 CH 4´´´´, 5´´´´ 1´´´´, 2´´´´, 
4´´´´, 5´´´´ 
4´´´´ 3.59 (dd, J = 
3.5, 1.5) 
74.4 CH 3´´´´, 5´´´´ 2´´´´, 3´´´´, 
5´´´´, 6´´´´ 
5´´´´ 4.04 (ddd, J 
= 1.5, 5.0, 
7.0) 
78.1 CH 4´´´´, 6´´´´ 1´´´´, 3´´´´, 
4´´´´, 6´´´´ 
6a´´´´ 3.75 (dd, J = 
10.0, 6.5) 
66.9 CH2 5´´´´ 4´´´´, 5´´´´ 
6b´´´´ 3.65 (dd, J = 
7.8, 3.5) 
    
a
d4-MeOH, 300 MHz. 
b
d4-MeOH , 125 MHz   
 
The middle region of the spectrum exhibited three anomeric signals due to the 
sugar units at δ 5.34, δ 5.45, and δ 4.04. The coupling constant of the anomeric proton of 
the pentose at δ 5.34 (J = 7.7 Hz) and for the hexose at δ 4.04 (J = 7.7) Hz was in 
accordance with a β-glycosidic linkage, while the coupling constant of another anomeric 
proton was for api-pentose (J = 1.5 Hz) indicated an α-glycosidic linkage (138). A 
further seventeen protons were identified between δ 3.31 and δ 4.04 due to the sugar 
units. The HMBC experiment of compound 5 exhibited a correlation of the anomeric 
proton H-1'' of α-D-arabinopyranose (δ 5.34) with C-3 (δC3 135.7), indicating the linkage 
of this sugar with the aglycone moiety. The interglycosidic linkage is shown by the 
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correlation of the H-1''' (δ 5.44) of α-D-apiose with the C-2'' (δ C2'' 76.9) of β-D-
arabinopyranose and by the correlation of the H-1'''' (δ 4.04) of β-D-glucopyranose with 
H-4'' (CH2 – (66.1) of β-D-arabinopyranose, hence confirming that two sugars are 
attached to the same pentose β-D-arabinopyranose, which is attached directly to 
kaempferol. Overall, the structure was confirmed on the basis of 2D NMR, and the new 
molecule was assigned as kaempferol-3-O-β-D-[-arabinopyranosyl-(1'''→2'')-O-α-L-
apiose-(1''''→5'')-O-β-Dglucopyranoside  (Figure 26). 
 
 
 
Figure 26 HMBC and 
1
H-
1
H COSY correlations of compound 5 
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In the previous report it was shown that fraction 3 possibly contained lipid-like 
glycosides. To understand the chemistry of the compounds present in F3, the fraction 
was subjected to normal phase chromatographic separation with IPA/Hex mobile phase 
using Si column Astec, Advance science technologies (10 × 250 mm, 5 μm) over 40 
min. One major compound F3A1 (6.5 mg) was isolated at R.T 21.4 min. Compound 
F3A1 gave a pinkish spot turning to violet on TLC while heating with 
anisaldehyde/sulphuric spray reagent indicating the possibility of conjugated glycol-
lipids. Moreover, the NMR spectrum for this compound was taken to elucidate the 
structure of this compound. The 
1
H NMR spectrum indicated again the presence of 
olefinic signals between δH 5.24-5.42 ppm, oxygenated signals between δH 3.55-4.40 
ppm, and α-methylene & further aliphatic signals between δH 2.8-0.8 ppm. The 
13
C 
NMR spectrum showed the presence of 3 carbonyl signals (δC 173.8, 173.5, 174.4), 6 
methine signals from the olefin (δC 137.9, 130.2, 129.9, 128.3, 128.2, 127.9, 127.8, 
127.1), an anomeric/acetal signal at δC 103.6 ppm, further 7 oxygenated signals 
containing 4 (-CH-O) signals and 3 (CH2-O) signals (δC 73.1, 72.3, 71.7, 70.0, 68.4, 
67.9, 62.2, 62.1) and several aliphatic methylene carbon signals and methyl carbon 
signals (δC 34.1, 31.9, 31.5, 30.9, 29.7, 29.6, 29.6, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 
29.2, 29.1, 29.1, 29.1, 29.0, 27.2, 25.6, 25.5, 25.3, 24.9, 24.8, 22.7, 22.6, 20.5, 14.3, 
14.1, 14.1). Intensity of the olefinic and aliphatic signals were higher than that of 
oxygenated (sugars) signals and this gave a tentative substructure for a 
glycolipid/sphingolipid type structure (Figure 27).  
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Figure 27 Structure of the isolated glycolipid from fraction F3A1 
 
 
Several studies on glycolipids reported them as having specific biological activities, e.g., 
anti-tumor  (139), anti-inflammatory (140), and anti-viral (141) properties.  
Chemistry Analysis of F2 Fractions (F2A, F2B and F2C) 
F2 obtained from the RPC18 cartridge was subjected to Silica gel chromatography 
(10 × 200 cm, 80 g) (eluted with hexane, dichloromethane and methanol in increasing 
polarity, step gradient) to obtain subfractions F2A, F2B, and F2C. The GC-MS 
chromatograms of F2A, F2B, and F2C are illustrated in Figure 28 and the potential 
compounds and additional data are shown in Tables 13-15, respectively.  F2A was non-
polar and hexane soluble fraction mainly consisting of fatty acids, volatile terpenes, 
simple phenols, etc. Further chemical components of F2A were revealed by GC-MS 
analysis. GCMS profile of fraction F2A identified 5-tetradecene, Cyclopropane 
Nonanoic acid, [2-butyl-], Cyclotetracosane, 5-Eicosene Androstane-3,17-diol[3β-5α 
1,2-Benzene dicarboxylic acid, butyl-7-ol,  Hexadecanoic acid 1-octadecanol,  Phytol,  
1,4 cyclo-octadiene Cyclohexane,  1,2-dimethyl-3-pentyl-4-propyl,  Cyclotracosane and 
Dibutyl phthalate (Table 13).  
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Figure 28 GCMS data of fraction F2A, F2B and F2C 
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Table 13 GC-MS data of F2A extract 
 
Peak 
Nos 
Retention 
time 
MW Identification Type of 
compound 
1 9.793 196 5-tetradecene Alkene 
2 11.416 322 Cyclopropane Nonanoic acid, [2-
butyl-] 
Lipid 
3 11.844 336 Cyclotetracosane Cycloalkane 
4 13.664 280 5-Eicosene Alkene 
5 14.629 292 Androstane-3,17-diol[3β-5α Diterpene 
6 14.717 334 1,2-Benzene dicarboxylic acid, butyl-
7-ol 
Phenolic acid 
7 15.090 256 Hexadecanoic acid Lipid 
8 15.331 270 1-octadecanol Alcohol 
9 16.186 296 Phytol Diterpene 
alcohol 
10 16.373 108 1,4 cyclo-octadiene Cyclo alkene 
11 16.855 224 Cyclohexane 1,2-dimethyl-3-pentyl-
4-propyl 
Substituted 
cycloalkane 
12 16.844 336 cyclotracosane Cyclo alkane 
13 18.303 278 Dibutyl phthalate Aromatic  
alkane 
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Table 14 GC-MS of F2B extract 
 
Peak No Retention time MW Identification Type of 
compound 
2 11.416 322 Cyclopropane 
Nonanoic acid, [2-
butyl-] 
Lipid 
4a 14.039 170 10-undecen-1ol Alcohol 
7a 15.134 168 Geranic acid monoterpene 
9 16.133 296 Phytol Diterpene 
10 16.373 108 1,4 cyclo-octadiene Cyclo alkene 
11a 16.890 541 - Tritepene 
12 17.614 544 - Triterpene 
12b 18.305 530 - tritepene 
13a 18.996 498 - triterpene 
 
 
Table 15 GC-MS of F2C extract 
 
Peak No Retention time MW Identification Type of 
compound 
2 11.416 322 Cyclopropane 
Nonanoic acid, 
[2-butyl-] 
Lipid 
4a 14.039 170 10-undecen-1ol Alcohol 
7a 15.134 168 Geranic acid Monoterpene 
9a 15.442 196 2,6-octadien-1-ol-
3,7,dimethyl 
acetate 
Alkene ester 
12a 16.177 533 - Triterpene 
13a 18.151 543 - Triterpene 
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Identified compounds belong to the class of lipid, cycloalkane, alkene, diterpene, 
and saturated alcohol. F2B was the middle polar fraction mainly comprising of 
triterpenes/sterols. TLC of this fraction gave a bluish violet color with anisaldehyde 
sulphuric acid spray on heating which again confirmed the presence of terpenoids. GC-
MS profile of F2B mainly identified the following compounds; GCMS profile of 
fraction F2B mainly identified as Cyclopropane Nonanoic acid, [2-butyl-],10-undecen-
1ol, Geranic acid, Phytol, 1,4 cyclo-octadiene and higher molecular weight terpenoids. 
Identified compounds mainly belong to the class of monoterpenes and triterpenes (Table 
14). The crude 
1
HNMR of F2B also revealed the olefinic protons and saturated aliphatic 
methines, N-methyl and aliphatic singlet methyls, hence the compound belongs to the 
triterpenoid class (Appendix F). F2C was obtained as a polar fraction from the silica gel 
column. The LC-MS profiles of F2C, F2, and F4 were similar, and the compounds 
identified in F4 were seen in the fraction F2C as well. GCMS profile of fraction F2C 
identified very few compounds in small amounts and were mainly identified as 
Cyclopropane Nonanoic acid, [2-butyl-]10-undecen-1ol, Geranic acid, 2,6-octadien-1-ol-
3,7,dimethyl acetate and higher molecular weight terpenoids. Identified compounds 
mainly belong to the class of monoterpene and triterpene Table 15. 
Chemical Analysis of F2C Subfractions (F2C1, F2C2, F2C3, and F2C4) 
The LC-MS chromatograms of F2C, F2C1, F2C2, F2C3 and F2C4 are illustrated 
in Figure 29 and the potential compounds and additional data are shown in Table 16, 
respectively.   
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Figure 29 LCMS chromatogram of sub-fractions obtained from fraction F2C 
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Table 16 Identified components from F2C fractions (F2C2, F2C2, F2C3, and F2C4) 
 
Peak 
no 
~R.T range UV MS [M-H]- MS
2
 Identification 
1 30.0 
253, 328, 
352 
755 
755, 
609, 
301 
Quercetin 3-O-
rhamnosyl-(1→2)-
[rhamnosyl-(1→6)]-
glucoside 
2 33.7 
242, 271, 
382 
593 
447,  
441, 
301 
Quercetin 3-O-
dirhamnoside 
3 35.4 
242, 265, 
299, 353 
609 301 Rutin 
4 36.8 
242, 266, 
307, 348 
463 
301, 
151 
Quercetin 3-O-glucoside 
 
5 42.8-43.0 
242, 266, 
345 
711 
579, 
463, 
396, 
329, 
287 
Identified by NMR 
[Kaempferol derivative] 
6 44.3-44.6 
242, 266, 
347 
579 
447, 
287 
kaempferol 3-[β-D-
xylofuranosyl-(1→6)-β-
D-galactopyranoside] 
7 45.0-46.4 
242, 266, 
345 
579 
447, 
287 
kaempferol 3-[β-D-
xylofuranosyl-(1→6)-β-
D-galactopyranoside] 
(isomer) 
8 46.4-47.5 
253, 328, 
354 
725 
725, 
579, 
287 
Kaempferol 3-O-
robinobioside-7-O-
arabinofuranoside 
9 49.3-50.3 
230, 242, 
270, 312 
451 
451, 
386, 
329, 
303, 
287, 
256, 
245, 
228 
Kaempferol 3-O-
glucoside 
10 50.8-54.3 
253, 328, 
354 
739 
739, 
579, 
287 
Kaempferol 3-O-
(rhamnosyl-glucoside)-
7-O-rhamnoside 
11 56.0-56.3 
230, 242, 
270, 315 
769 
769, 
317, 
609 
Isorhamnetin 3-O-
rhamnoside-7-O-
(rhamnosyl-hexoside) 
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The identification of flavonoids was achieved by comparison of MS
2
 
fragmentation pattern, UV spectra (nm), and retention time (RT) with data reported in 
the literature. The MS
2 
data mining process began with the identification of aglycone 
fragment in order to determine the flavonoid backbone of each compound, thus quercetin 
([M-H] m/z 301 uma), isorhamnetin ([M-H] m/z 315 uma), and kaempferol ([M-H] m/z 
285 uma) were found. The next step was to determine the number and type of sugar units 
attached to each flavonoid skeleton. The MS
2
 analysis of the precursor ions from 1, 2, 3 
and 9 yielded major MS
2
 fragment at m/z 301, thus, these compounds were tentatively 
identified as quercetin O-glycosides. The fragmentation pattern of compound 1, at m/z 
755 [(M-H)]
-
, yielded ions at m/z 596 [(M-H)-162]
-
, m/z 609 [(M-H)-146]
-
, and m/z 301 
[(M-H)-162-146-146]
-
. The tri-glycoside 1 identified as quercetin 3-O-rhamnosyl-
rutinoside and the fragmentation pattern reported (142) is similar to data obtained in this 
study. Compound 2, precursor ion at m/z 593 [(M-H)]
-
, generated fragments at m/z 447 
[(M-H)-146]
-
 and m/z 301 [(M-H)-146-162]
-
, and compound 3, precursor ion at m/z 
609[(M-H)+7]
-
, showed fragments at m/z 467 [(M-H)-146]
-
 and m/z 301 [(M-H)-146-
162]
-
. Both compounds were classified as di-glycosides. Compound 3 was identified as 
quercetin 3-O-rutinoside (rutin), a well-known flavonoid, previously described in 
Opuntia species (143, 144). Compound 4 gave [M-H]
-
 m/z at 463 and the MS
2
 analysis 
of precursor ion at m/z 463,  yielded the fragments at m/z 301 [(M-H)-162]
-
. Compound 
4 was identified as quercetin 3-O-glucoside, according to the fragmentation pattern in 
the literature (145). 
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The MS
2
 fragmentation pattern of compounds 5-11 showed fragments at m/z 285, 
allowing tentatively to identify these compounds as kaempferol O-glycosides. 
Compound 5 gave [M-H]
- 
m/z 711; yielded fragments at m/z 579 [M-H-132]
-
 and m/z 
285
 
[M-H-132-146-132]
- 
and its structure was identified with NMR as mentioned 
previously. Compounds 6 and 7, both with same precursor ion at m/z 579 [(M-H)]
- 
but 
different RT, yielded similar fragment m/z 285 [(M-H)-146-162]
-
, thus these compounds 
are isomers comparing these data with MS
2
 fragments and UV spectra reported in the 
literature (146). Compound 8 and 10 gave [M-H]
-
 m/z 725 and MS
2
 fragments for 725 
yielded fragments at 579 [M-H]-146]
-
 and at m/z 447 [M-H]-146-132] and at m/z [M-H]-
146-132-162]. According to these fragments, three different sugar units, such as hexose 
(162 uma), a deoxyhexose (146 uma) and a pentose (132 uma) are attached to a 
kaempferol molecule. The compound 10 with precursor ion at m/z 739 [(M-H) ]
- 
yielded 
fragments at m/z 579 [(M-H)-146-18]
-
, m/z 598.5[(M-H)-146]
-
 and m/z 285 [(M-H)-146-
146-162]
-
. These tri-glycosides were identified as kaempferol 3-O-robinobioside-7-
alpha-L-arabinofuran-oside (8) and kaempferol 3-O-(rhamnosyl-hexoside)-7-O-
rhamnoside II (10). Ginestra et.al. reported similar kaempferol 3-O-tri-glycos-ides in O. 
ficus-indica stems (143). The compound 11 was identified as isorhamnetin O-glycoside 
due to the presence of a fragment ion at m/z 317. The compound 11, precursor ion at m/z 
770 [(M-H)]
-
, yielded fragments at m/z 609 [(M-H)-162]
-
and at m/z 317 [(M-H)-162-
132-162]
-
. This compound, a tri-glycoside according to these fragments, was identified 
as isorhamnetin 3-O-(pentosyl-glucoside)-7-O-glucoside. The fragmentation pattern of 
this compound was similar to the flavonoid present in honey (147).  
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 Additionally, F2C1, F2C2, F2C3 and F2C4 were subjected to GCMS analyses, 
no peaks were observed in fractions F2C1, F2C2 and F2C3. TLC of HPLC fraction 
F2C4 showed positive in the Liebrmann-Buchhard test for terpenoids and anisaldehyde/ 
sulphuric acid spray reagent for general flavonoids and terpenoids. The GC-MS 
chromatograms of F2C4 is illustrated in Figure 30 and the potential compounds and 
additional data are shown in Table 17, respectively GC-MS analysis shows that F2C4 
contains some terpenoids, which is shown by the m/z 162, 533 and 543 and 401 could 
not be identified from the library database. A crude 
1
H NMR revealed the presence of 
aliphatic, acetyl, oxygenated and olefinic signals between δH 5.5-0.9 ppm. Further 
purification and detailed NMR analysis and characterization will reveal the components 
in the active fraction.  
 
 
Figure 30 GCMS data of F2C4 extract 
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Table 17 GC-MS of F2C4 extract 
 
Peak Nos Retention time MW Identification Type of 
compound 
11b 18.29 162.9 NI - 
12a 18.35 533 NI - 
13a 18.53 543 NI - 
13b 19.01 401 NI  
 
 
Binding and Inhibition of COX-2 Activity by Acerola Leaf Extract and Fractions  
The effect of acerola leaf extract (F4) and fractions (F1, F2, and F3) on COX-2 
activity is shown in Figure 31. The acerola leaf extract and fractions 2 and 3 at two 
concentrations significantly reduced the COX-2 activity when compared to the control. 
Among all treatments, F4 and F2 had the highest inhibitory effect on COX2 activity, and 
thus were selected to confirm the binding to COX-2 by DARTS methodology. DARTS 
results followed by western blot analysis showed that F2 and F4 protected COX-2 from 
proteolysis, indicating binding of the phytochemicals present in F4 and F2 fractions to 
COX-2 (Figure 32).  
Binding and Inhibition of COX-2 Activity by Acerola F2 Subfractions 
The phytochemicals present in F2 bound to COX-2 and showed the highest 
inhibitory effect of COX2 activity among all the fractions. In order to identify the group 
of phytochemicals responsible for inhibiting COX2 activity, F2 was further fractionated 
into F2A, F2B, and F2C. The effect of F2 subfractions (F2A, F2B, and F2C) on COX-2 
activity is shown in Figure 33. 
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Figure 31 Effect of acerola leaves extract and fractions on COX-2 enzyme activity. 
According to the instruction of the COX Inhibitor Screening Assay Kit (Cayman 
Chemical, Ann Arbor, MI), COX-2 enzyme was incubated with acerola leaves extract 
(F4) or fractions (F1, F2 or F3) and then its activity was examined by measuring the 
level of PGE2α. Data, obtained from at least three biological repeats are shown as mean 
± SE values. Different letters indicate significant differences by the ANOVA/Tukey-
HSD (p < 0.05).    
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Figure 32 Evaluation of the binding of phytochemicals from acerola leaf extract (F4) or 
fraction (F2) to COX-2 by DARTS methodology. RAW 264.7 cell lysates were 
incubated with 400 µg/ml of acerola leaf extract (F4) or fraction (F2) for 3 h at room 
temperature, and then proteolized with pronase for 25 min at room temperature, 
followed by Western blot analysis. Data, obtained from three biological repeats at least, 
are shown as mean ± SE values. Symbols indicate significant differences by Student’s t 
test (#p < 0.1,*p < 0.05).  
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Figure 33 Effect of acerola F2 fractions on COX-2 enzyme activity. According to the 
instruction of the COX Inhibitor Screening Assay Kit (Cayman Chemical, Ann Arbor, 
MI), COX-2 enzyme was incubated with 200 µg/ml of F2 fractions (F2A, F2B or F2C) 
or 50 nM DuP-697, and then its activity was examined by measuring the level of 
PGE2α. Data, obtained from at least three biological repeats are shown as mean ± SE 
values. Different letters indicate significant differences by the ANOVA/Tukey-HSD (p < 
0.05).    
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Results showed that all fractions at 200 µg/ml significantly inhibit COX2 
activity. To assess the binding of these subfractions to COX-2, DARTS methodology 
was performed. Results showed that after 25 min of pronase digestion, only F2C 
protected COX-2 protein band when compared to the control, while F2A and F2B did 
not show a protection (Figure 34A). However, when the time was reduced to 10 min, 
both F2A and F2C protected COX-2 protein band when compared to the control (Figure 
34B).  
Inhibition of COX-2 Activity by Acerola F2C Subfractions and by Individual 
Phenolics of Acerola Leaf  
 The phytochemicals present in F2C bound to COX-2 and showed an inhibitory 
effect of COX2 activity. In order to identify the group of phytochemicals responsible for 
inhibiting COX2 activity, F2C was further fractionated into F2C1, F2C2, F2C3, and 
F2C4. The effect of F2C subfractions (F2C1, F2C2, F2C3, and F2C4) on COX-2 activity 
is shown in Figure 35. Interestingly, only F2C4 showed COX-2 inhibitory activity, 
indicating the presence of the phytochemicals with COX-2 inhibitory properties in this 
subfraction. Three major phenolics from acerola leaf fraction F2C were isolated as P1 
(compound 5), P2 (compound 6) and P3 (compound 7) and its COX-2 inhibitory 
properties were evaluated. Figure 36 shows that none of the isolated phenolics inhibited 
COX-2. 
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Figure 34 Evaluation of the binding of phytochemicals from acerola F2 fractions (F2A, 
F2B or F2C) to COX-2 by DARTS methodology. RAW 264.7 cell lysates were 
incubated with 400 µg/ml of acerola F2 fractions (F2A, F2B or F2C) for 3 h at room 
temperature, and then proteolized with pronase for 25 min (A) or 10 min (B) at room 
temperature, followed by Western blot analysis. Data, obtained from three biological 
repeats at least are shown as mean ± SE values. Symbols indicate significant differences 
by Student’s t test (#p < 0.1,*p < 0.05).  
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Figure 35 Effect of acerola F2C fractions on COX-2 enzyme activity. According to the 
instruction of the COX Inhibitor Screening Assay Kit (Cayman Chemical, Ann Arbor, 
MI), COX-2 enzyme was incubated with 200 µg/ml of F2C fractions (F2C1, F2C2, 
F2C3 or F2C4) or 50 nM DuP-697, and then its activity was examined by measuring the 
level of PGE2α. Data, obtained from at least three biological repeats are shown as mean 
± SE values. Different letters indicate significant differences by the ANOVA/Tukey-
HSD (p < 0.05).    
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Figure 36 Effect of acerola penolics COX-2 enzyme activity. P1(Compound 5), P2 
(Compound 6) and P3 (compound 7). According to the instruction of the COX Inhibitor 
Screening Assay Kit (Cayman Chemical, Ann Arbor, MI), COX-2 enzyme was 
incubated with 200 µg/ml of F2C fractions (F2C1, F2C2, F2C3 or F2C4) or 50 nM DuP-
697, and then its activity was examined by measuring the level of PGE2α. Data, 
obtained from at least three biological repeats are shown as mean ± SE values. Different 
letters indicate significant differences by the ANOVA/Tukey-HSD (p < 0.05).  
 
 
Discussion  
Cyclooxygenase (COX) is an enzyme that is responsible for the formation of 
prostanoids, including prostaglandins, prostacyclin, and thromboxane (148, 149).It 
includes two isoforms, COX-1 and COX-2, whose expressions are regulated differently; 
COX-1 is expressed constitutively and is responsible for the supply of prostaglandins 
which maintain the integrity of the gastric mucosa and provide adequate vascular 
homeostasis whereas COX-2 expression is induced by an inflammatory stimulus, 
hormones, and growth factors (150-152).  The COX-2 isoform is mainly responsible for 
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the production of prostanoids in inflammation and in proliferative diseases, such as 
cancer (152). Thus, COX-2 has become an important target in inflammation and related 
diseases (153). 
In previous work from our group, we showed that acerola leaf extracts and 
fractions reduce prostaglandin E2 (PGE2) levels in LPS-stimulated RAW 264.7 (Not 
Published) macrophages. COX catalyzes the synthesis of prostaglandin H2 (PGH2) from 
arachidonic acid, and Prostaglandin E Synthase uses PGH2 to produce PGE2 (154). 
Since COX2 is involved in the production of PGE2, we decided to evaluate this enzyme 
as a target of the phytochemicals present in acerola leaves. In this study, we used 
bioassay-guided fractionation and DARTS to identify the bioactive compounds acting as 
COX-2 inhibitors from acerola leaf. In this strategy, the COX-2 inhibitory activity of 
extracts or fractions was evaluated by an enzymatic assay and the binding of this 
phytochemicals to COX-2 was identified using DARTS. The results of this study 
showed that acerola leaf extract and fractions 2 and 3, contain phytochemicals that 
inhibit COX2 activity. LC-MS and NMR analysis revealed that F3 contains a main 
compound with glycerol/glycolipid/sphingolipid type structure. Several studies have 
shown that compounds with similar structures inhibit COX-2 (155, 156), and thus this 
compound could be responsible for the COX-2 inhibitory properties of F3. On the other 
hand, the previous report showed that F2 contains quercetin and kaempferol O-
glycosides, terpenes and alkenes (Bang et al., Unpublished). Since F2 showed the 
highest COX-2 inhibitory effect among the fractions, and also showed binding to COX-2 
by DARTS, its fractions (F2A, F2B, and F2C) were further tested for their ability to bind 
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and inhibit COX-2 activity. Our results showed that all subfractions inhibit COX-2 
activity but only F2C protected COX-2 protein band after 25 min of pronase digestion in 
DARTS methodology (Figure 34 A). The binding of a small molecule to an enzyme can 
be reversible or irreversible (157), which may affect the target protein protection in 
DARTS methodology. If the rate of binding and unbinding of the small molecule 
remains constant or somewhat constant, the small molecules that bind reversibly, may 
protect the target protein only in short protease digestion times, while irreversible 
molecules may protect it in short and long digestion times. The fact that all F2 fractions 
inhibited COX-2 activity, but only F2C showed binding by DARTS, lead us to 
hypothesize that the phytochemicals in F2A and F2B might bind reversibly to COX-2. 
To proof this concept, we reduce the proteolysis time to 10 min in DARTS 
methodology.  Results showed that F2A and F2C protected COX-2 protein band at 10 
min (Figure 34 B), indicating that the phytochemicals in F2A may bind reversibly to 
COX2 while the phytochemicals in F2C may bind irreversibly. However the type of 
binding of these phytochemicals to COX2 should be validated with further studies. The 
fraction F2B did not protect COX-2 protein band at 25 or 10 min. It is possible that due 
to the reversible binding of its phytochemicals, a band protection could only be observed 
in less than 10 min of protease digestion or that the binding to COX2 by this 
phytochemicals did not protect the enzyme from protease digestion.  
GC-MS profiling revealed that F2A contains alkenes and terpenes, while F2B 
contains mainly terpenes. Both alkenes and terpenes have been shown to inhibit COX2 
activity (158, 159) and could account for the COX-2 inhibitory properties of these 
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sufractions. The LCMS profile of F2C was similar to the previously reported profiles of 
F2 and F4, and indicated the presence of flavonoids. In addition, the GC-MS profiling 
revealed F2C contain small amounts of terpenoids. In order to further identify the 
bioactive phytochemicals, F2C was fractionated into F2C1, F2C2, F2C3 and F2C4. 
Interestingly, only fraction F2C4 containing aliphatic triterpene like compounds 
inhibited COX-2 activity. These results indicate that terpenes are responsible for the 
COX-2 inhibitory properties of F2C. In agreement with these results, the three major 
phenolics isolated from acerola leaf F2C did not show COX-2 inhibitory properties.  
In this study we showed that acerola leaves have potential COX-2 inhibitors, 
which were identified by bioassay-guided fractionation and DARTS methodology. The 
phytochemicals responsible for the inhibition of COX-2 seem to belong to the terpene, 
alkene and glycolipid/sphingolipid groups of compounds.  Additionally, two new 
compounds, a kampeferol glycoside and a glycolipid like compound from acerola leaf, 
were identified in this study. Moreover, we showed that DARTS methodology can be 
used as a screening technique if different digestion times are considered. In addition, 
DARTS may provide information on the type of binding of small molecules to their 
protein target, however this would need to be verified by other methodologies.  
 
 
 
 
 121 
 
CHAPTER IV                                                                                                           
CONCLUSIONS 
 
In conclusion, we demonstrated that the extracts from mashua have anti-
inflammatory properties in vitro. Through the DARTS methodology, PKM was 
identified as a potential target of mashua 203040 and 203081 extracts. In addition, 
mashua extracts exerted their anti-inflammatory properties and attenuated the Warburg-
like effect by suppressing ROS levels and consequently interfering with different ROS-
responsive signaling proteins including NF-κB and HIF. The compounds in mashua 
responsible for the anti-inflammatory properties are both phenolics and isothiocyanates.  
Additionally, we showed that LPS-challenged RAW264.7 macrophages exhibit a 
Warburg-like effect. RAW264.7 cell line are frequently used as a model in inflammation 
studies and the Warburg effect has been shown to be crucial for macrophage activation. 
Thus, this study defines some of the changes that RAW264.7 cell line exhibits in relation 
to the to the Warburg effect, upon the challenge with LPS.    
 Furthermore, we showed that acerola leaves have potential COX-2 inhibitors, 
which were identified by bioassay-guided fractionation and DARTS methodology. The 
phytochemicals responsible for the inhibition of COX-2 seem to belong to the terpene, 
alkene and glycolipid/sphingolipid groups of compounds. Moreover, two new 
compounds, a kampeferol glycoside and a glycolipid like compound from acerola leaf, 
were identified in this study.  
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Finally, we showed that DARTS methodology can be used to identify putative 
protein targets of phytochemicals present in plant extracts. In addition, DARTS could be 
used as a screening technique if different digestion times are considered. Also, DARTS 
may provide information on the type of binding of small molecules to their protein 
target, however this would need to be verified by other methodologies.  
Further studies should be done to identify the specific compound or combination 
of compounds responsible for the anti- inflammatory properties of mashua and acerola 
leaf. In addition, the anti-inflammatory properties of mashua tuber and acerola leaf 
should be evaluated in other cells such as adipocytes or endothelial cells due to the 
important role of these cells in the development of differed metabolic diseases.  
Moreover, the beneficial properties of both plants should be evaluated in vivo and a 
recommended consumption dose, to obtain those benefits, should be established.  
Finally different strategies to make DARTS methodology more sensitive should 
be explored. Also, the proposed concept of the reversible and irreversible binding of 
small molecules in DARTS should be validated by using known drugs.  
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APPENDIX  
 
 
Appendix A HPLC-MS chromatogram of the total acerola leaf extract at 365 nm. 
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Appendix B Identified components from the Acerola leaves extract (crude extract F4) 
 
Peak 
no 
Retention time UV 
MS 
[M-H]- 
MS
2
 Identification 
1 29.3 
253, 328, 
352 
755 
755, 609, 
301 
Quercetin 3-O-
rhamnosyl-(1→2)-
[rhamnosyl-(1→6)]-
glucoside 
2 38.3 
242, 271, 
382 
593 
447,  441, 
301 
Quercetin 3-O-
dirhamnoside 
3 40.4 
242, 265, 
299, 353 
609 301 Rutin 
4 40.8 
242, 266, 
307, 348 
463 301, 151 
Quercetin 3-O-
glucoside 
 
5 42.4 
242, 266, 
345 
711 
579, 463, 
396, 329, 
287 
Identified by NMR 
[Kaempferol 
derivative] 
6 44.7 
242, 266, 
347 
579 447, 287 
kaempferol 3-[β-D-
xylofuranosyl-(1→6)-
β-D-galactopyranoside] 
7 47.9 
242, 266, 
345 
579 447, 287 
kaempferol 3-[β-D-
xylofuranosyl-(1→6)-
β-D-galactopyranoside] 
(isomer) 
8 48.5 
253, 328, 
354 
725 
725, 579, 
287 
Kaempferol 3-O-
robinobioside-7-O-
arabinofuranoside 
9 53.6 
230, 242, 
270, 312 
451 
451, 386, 
329, 303, 
287, 256, 
245, 228 
Kaempferol 3-O-
glucoside 
10 62.6 
253, 328, 
354 
739 
739, 579, 
287 
Kaempferol 3-O-
(rhamnosyl-glucoside)-
7-O-rhamnoside 
11 65.4 
230, 242, 
270, 315 
769 
769, 317, 
609 
Isorhamnetin 3-O-
rhamnoside-7-O-
(rhamnosyl-hexoside) 
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Appendix C GCMS of F4 extract 
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Appendix D GC-MS of F4 extract 
 
Peak no Retention time MW Identification Type of 
compound 
1 9.793 196 5-tetradecene Alkene 
2 11.416 322 Cyclopropane 
Nonanoic acid, 
[2-butyl-] 
Lipid 
3 11.844 336 Cyclotetracosane Cycloalkane 
4 13.664 280 5-Eicosene Alkene 
     
5 14.629 292 Androstane-
3,17-diol[3β-5α 
Diterpene 
6 14.717 334 1,2-Benzene 
dicarboxylic 
acid, butyl-7-ol 
Phenolic 
acid 
7 15.090 256 Hexadecanoic 
acid 
Lipid 
8 15.331 270 1-octadecanol Alcohol 
9 16.186 296 Phytol Diterpene 
alcohol 
10 16.373 108 1,4 cyclo-
octadiene 
Cyclo alkene 
11 16.855 224 Cyclohexane 
1,2-dimethyl-3-
pentyl-4-propyl 
Substituted 
cycloalkane 
11a 16.890 541 - Tritepene 
12 16.844 336 cyclotracosane Cyclo alkane 
12a 16.177 533 - Triterpene 
12b 18.305 530 - Tritepene 
13 18.303 278 Dibutyl 
phthalate 
Aromatic  
alkane 
13a 18.151 543 - Triterpene 
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Appendix E HPLC-MS chromatograms of acerola leaf extract (F4) and fractions (F1, 
F2, and F3) at 365 nm.   
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Appendix F 1H NMR of crude fraction F2B Acetone-d6 
 
 
 
 
